Enovix Corp 8-K, filed Nov 18, 2026
Enovix Corp (ENVX)
About this 8-K
Enovix Corp filed this 8-K on November 18, 2026.
Enovix will distribute warrants on November 18, 2026, to holders of record of common stock as of November 13, 2026, at one warrant for every four shares. Holders of its 3.00% Convertible Senior Notes due 2028 and 4.75% Convertible Senior Notes due 2030 also receive warrants. Each warrant has an exercise price of $3.00 and expires April 28, 2028, unless an early expiration price condition is met. AI summary
Items reported
- Item 1.01: Entered into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):

(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
Telephone Number, Including Area Code: (
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
As previously disclosed, on October 28, 2026, Enovix Corporation, a Delaware corporation (the “Company”), announced that the Board of Directors of the Company declared a distribution (the “Warrant Distribution”) to the holders of record of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in the form of warrants to purchase shares of Common Stock (the “Warrants”). The Warrants were issued on the terms and conditions described in the Warrant Agreement (as defined below and attached as an exhibit hereto) and are being distributed on November 18, 2026, to the holders of record of Common Stock as of the close of business on November 13, 2026 (the “Record Date”).
Pursuant to the terms of the Warrant Agreement, dated as of November 18, 2026, between the Company, Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., as Warrant Agent (the “Warrant Agent”) (such agreement, the “Warrant Agreement”), each holder of record of Common Stock as of the Record Date will receive one Warrant for every four shares of Common Stock (rounded down to the nearest whole number for any fractional Warrant). Holders (“other eligible recipients”) of our 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and the Company’s 4.75% Convertible Senior Notes due 2030 (collectively with the 2028 Notes, the “Convertible Notes”) will also receive, at the same time and on the same terms as holders of Common Stock, Warrants without having to convert such other eligible recipient’s Convertible Notes as if each such holder of Convertible Notes held a number of shares of Common Stock equal to the product of (i) the conversion rate applicable to the Convertible Notes in effect on the Record Date, and (ii) the aggregate principal amount (expressed in thousands) of Convertible Notes held by such noteholder on such date.
Each Warrant will entitle the holder to purchase, at the holder’s sole and exclusive election, at an exercise price of $3.00 per Warrant (the “Warrant Exercise Price”), one share of Common Stock payable in cash. The Warrants may also be exercised, at the election of the holder, by delivery of certain issued and outstanding notes that may be designated by the Company from time to time pursuant to the terms of the Warrant Agreement (the “Designated Notes”) by delivering an amount equal to $1,000 principal amount of Designated Notes to exercise up to 333 Warrants (subject to certain adjustments). The Company has initially designated the 2028 Notes as Designated Notes.
Unless the Early Expiration Price Condition (defined below) is met, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on the date (the “Expiration Date”) which is (i) April 28, 2028 or (ii) if the Early Expiration Price Condition occurs, the Early Expiration Date, where “Early Expiration Date” means either (x) the first Scheduled Trading Day (defined below) immediately following the Early Expiration Price Condition Date (defined below) (subject to the terms of the Warrant Agreement) (the “Scheduled Early Expiration Date”) or (y) if the Company elects to set an Alternate Early Expiration Date (defined below), such Alternate Early Expiration Date.
Upon the occurrence of the first 30 consecutive Trading Day (defined below) period (the “Reference Period”) that includes 20 Qualifying Trading Days (defined below) (whether or not consecutive) the first of which 20 Qualifying Trading Days must fall on or after the first Trading Day immediately following the distribution date of the Warrants (the “Early Expiration Price Condition”, and the last of such 20 Qualifying Trading Days (whether or not consecutive) to occur, the “Early Expiration Price Condition Date”), the Expiration Date will automatically accelerate to the Scheduled Early Expiration Date, unless the Company sets an Alternate Early Expiration Date (defined below) in accordance with the provisions described below and as further described in the Warrant Agreement, in which case the Early Expiration Date will be such Alternate Early Expiration Date. In the event of an early expiration of the Warrants, Warrants will be exercisable until 5:00 p.m. New York City time on the Early Expiration Date. If the Early Expiration Price Condition occurs, the Company will make a public announcement by issuance of a press release to that effect as promptly as practicable after market close on the Early Expiration Price Condition Date setting forth the Early Expiration Date or an Alternate Early Expiration Date. Subject to applicable laws and regulations and the terms of the Warrant Agreement, including the occurrence of the Early Expiration Price Condition or the Additional Price Conditions (defined below), the Warrants may be exercised at any time starting on the date of issuance until 5:00 p.m. New York City time on the Expiration Date.
1
The Company may, in its sole discretion, elect to set the Early Expiration Date on a Scheduled Trading Day falling after the Scheduled Early Expiration Date (such date, an “Alternate Early Expiration Date”). In order to exercise the right to set an Alternate Early Expiration Date, the Company shall, no later than the fifth Qualifying Trading Day (whether or not consecutive) occurring in any 20 consecutive Trading Day period ending on or before the next following Early Expiration Price Condition Date (if any), make a public announcement by issuance of a press release that the Company is reserving the right to set an Alternate Early Expiration Date in the event the Early Expiration Price Condition does occur. If the Company sets an Alternate Early Expiration Date, the expiration of the Warrants on such Alternate Early Expiration Date shall be conditioned on (x) in respect of each of the two consecutive Scheduled Trading Days immediately preceding such Alternate Early Expiration Date, no Market Disruption Event (as defined in the Warrant Agreement) occurring and (y) the Daily VWAP (defined below) on each of such two consecutive Scheduled Trading Days immediately preceding such Alternate Early Expiration Date being at least equal to the quotient obtained by dividing the Warrant Exercise Price by the then-current Warrant Exercise Rate (as defined in the Warrant Agreement) (the “Additional Price Conditions”). As promptly as practicable after close on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date, the Company will make a public announcement by issuance of a press release as to whether the Additional Price Conditions are met. The Company may, in its sole discretion, postpone such Alternate Early Expiration Date to a new Alternate Early Expiration Date (which, for the avoidance of doubt, shall be conditional upon the Additional Price Conditions in respect of the Alternate Early Expiration Date so postponed). The Company may, in its sole discretion, postpone further (on one or more occasions) such Alternate Early Expiration Date of the Warrants to a new Alternate Early Expiration Date (which, for the avoidance of doubt, shall be conditional upon the Additional Price Conditions with respect to the Alternate Early Expiration Date as so postponed). The Company will make a public announcement of any such postponement by issuance of a press release as promptly as practicable after the close of regular market hours of Nasdaq on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date to be so postponed. If the Additional Price Conditions are not met as to an Alternate Early Expiration Date specified by the Company, unless the Company sets a new Alternate Early Expiration Date as set forth in the preceding paragraph (an “Alternate Early Expiration Date Annulment”), the Expiration Date will remain April 28, 2028 unless another Early Expiration Price Condition Date subsequently occurs. The definitions of Early Expiration Price Condition, Early Expiration Price Condition Date and Reference Period are subject to appropriate adjustment as set forth in the Warrant Agreement in the event of an Alternate Early Expiration Date Annulment.
All or any part of the Warrants may be exercised prior to 5:00 p.m. New York City time on the Expiration Date (as it may be adjusted) by delivering to the Warrant Agent a duly executed notice of election and the Warrants being exercised, and payment of the Warrant Exercise Price in cash or, if there are Designated Notes, by delivery of Designated Notes.
For the purposes of the foregoing, “Daily VWAP” of a share of Common Stock (or a Warrant or other security) on any date of determination means (i) in the case of a share of Common Stock, for any day on which trading in the Common Stock generally occurs on the Nasdaq Global Select Market (the “Exchange”) (or, if the Common Stock is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock on such day), the per-share volume-weighted average price in the consolidated tape system during regular market hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVX US Equity AQR” (or its equivalent successor if such page or setting is not available) in respect of such day, (ii) in the case of a Warrant, for any day on which trading in the Warrant generally occurs on the Exchange (or, if the Warrant is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Warrants on such day), the per-warrant volume-weighted average price in the consolidated tape system during regular market hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVXW US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day, and (iii) in the case of any other security, for any day on which trading in such security generally occurs on the Exchange (or, if the security is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of such security on such day), the per-share volume-weighted average price in the consolidated tape system during regular market hours as displayed on Bloomberg page “AQR” for such security in respect of such day. If such information is not so available for the Common Stock or such Warrant or other security, the Daily VWAP on such date shall be the last reported sale price for the Common Stock or such Warrant or other security on such day.
2
A “Trading Day” for the purposes of the foregoing definition means a day on which the Common Stock (or Warrant or other security, as the case may be) (i) at the close of regular way trading (not including after-hours or extended market trading) is not suspended from trading on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, any U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be) at the close of business, and (ii) has traded at least once regular way on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, such other U.S. national securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be); provided that if the Common Stock (or Warrant or such other security, as the case may be) is not so listed or traded, “Trading Day” means a Business Day (as defined in the Warrant Agreement).
A “Qualifying Trading Day” for purposes of the foregoing means any S+W Trading Day (defined below) on which the Daily VWAP of the Common Stock on such Trading Day is at least equal to the Early Expiration Trigger Price (defined below) in effect on the last day of the Reference Period (subject to the conditions and limitations set forth in the Warrant Agreement). An “S+W Trading Day” means any day which is a Trading Day for both the Common Stock and the Warrants.
A “Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange on which the Common Stock is listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, the principal market on which the Common Stock is admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day.
The “Early Expiration Trigger Price” is initially equal to $3.30, subject to certain adjustments.
The number of shares of Common Stock issuable upon exercise of the Warrants is subject to certain anti-dilution adjustments, including for stock dividends, splits, subdivisions, reclassifications and combinations, other distributions and spin-offs, and shareholder rights plans. In addition, the Warrant Exercise Rate may be voluntarily increased by the Company from time to time.
The Warrants are expected to commence trading on the Nasdaq Stock Market LLC under the ticker “ENVXW” on November 19, 2026.
The foregoing description of the Warrants and the Warrant Agreement is only a summary and is qualified in its entirety by reference to the complete description of the terms of the Warrants set forth in the Warrant Agreement (including the Form of Warrant attached thereto), which is filed as an exhibit to this Form 8-K. In connection with the Warrant Distribution, the Company is filing a prospectus supplement, dated November 18, 2026, pursuant to the Company’s existing shelf registration statement on Form S-3, declared effective on November 9, 2026, registering up to $500,000,000 of shares of Common Stock, including the shares of Common Stock to be issued upon exercise of the Warrants, under the Securities Act of 1933, as amended (the “Securities Act”).
3
Item 7.01 Regulation FD Disclosure.
On November 18, 2026, the “Company” issued a press release announcing the Warrant Distribution to its shareholders and other eligible recipients as of the November 13, 2026 Record Date. The press release is attached as Exhibit 99.1 to this Form 8-K.
Also on November 18, 2026, the Company posted a further FAQ regarding the Warrant Distribution to the Company’s website (the “FAQ”). The FAQ is attached as Exhibit 99.2 to this Form 8-K. The Company previously announced the Warrant Distribution on October 28, 2026 and published an initial set of questions and answers on its website, which was furnished as Exhibit 99.2 to the Company’s Form 8-K filed on October 28, 2026.
The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms of the Warrants were filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2026 and are available on the SEC’s website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This communication contains a general summary of the Warrants. Please read the Warrant Agreement as it contains important information about the terms of the Warrants.
Forward-Looking Statements
This Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about the Company, the Warrants and the Warrant Distribution. Forward-looking statements generally relate to future events and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, should, would and similar expressions that convey uncertainty about future events or outcomes. Actual results and outcomes could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, those risks and uncertainties and other potential factors set forth in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that the Company has filed, or that it will file, with the SEC. Any forward-looking statements made by the Company in this Form 8-K, including any forward-looking statements made by the Company in any of the exhibits to this Form 8-K, speak only as of the date on which they are made and subsequent events may cause these expectations to change. The Company disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise, except as required by law.
4
Item 9.01 Financial Statements and Exhibits.
On November 18, 2026, Arnold & Porter Kaye Scholer LLP delivered an opinion (the “Opinion”) to the Company in connection with the Company’s issuance of up to 62,329,657 shares of Common Stock upon exercise of the Warrants. Such shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (No. 333-299760) (the “Registration Statement”), which was declared effective on November 9, 2026, including the prospectus, dated November 9, 2026, and the prospectus supplement, dated November 18, 2026, as the same may be amended or supplemented. The Opinion is being filed herewith as Exhibit 5.1, and thereby automatically incorporated by reference into the Registration Statement, in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.
(d) Exhibits
| Exhibit Number | Description | |
| 4.1 | Warrant Agreement (including Form of Warrant), dated November 18, 2026, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent. | |
| 5.1 | Opinion of Arnold & Porter Kaye Scholer LLP | |
| 23.1 | Consent of Arnold & Porter Kaye Scholer LLP (included in Exhibit 5.1). | |
| 99.1 | Press Release dated November 18, 2026 | |
| 99.2 | Warrant Dividend Distribution FAQ dated November 18, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
5
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Enovix Corporation | ||
| Date: November 18, 2026 | By: | /s/ Ryan Benton |
| Ryan Benton Interim Chief Executive Officer and Chief Financial Officer | ||
6
Exhibit 4.1
WARRANT AGREEMENT
Dated as of NOVEMBER 18, 2026
between
ENOVIX CORPORATION
and
COMPUTERSHARE INC. AND COMPUTERSHARE TRUST COMPANY N.A.
collectively, as Warrant Agent
Warrants
for
Shares of Common Stock of
ENOVIX CORPORATION
TABLE OF CONTENTS
| Page | ||
| ARTICLE I | ||
| DEFINITIONS | ||
| Section 1.01 | Definitions | 1 |
| Section 1.02 | Other Definitions | 7 |
| Section 1.03 | Rules of Construction | 8 |
| ARTICLE II | ||
| FORM OF WARRANT; BENEFICIAL INTERESTS | ||
| Section 2.01 | Issuance and Registration | 8 |
| Section 2.02 | Warrant Certificates | 10 |
| Section 2.03 | Warrant Register | 11 |
| Section 2.04 | Transfer and Exchange | 11 |
| Section 2.05 | Definitive Warrants | 13 |
| Section 2.06 | Replacement Certificates | 14 |
| Section 2.07 | Outstanding Warrants | 14 |
| Section 2.08 | Cancellation | 14 |
| Section 2.09 | CUSIP Numbers | 15 |
| ARTICLE III | ||
| EXERCISE TERMS | ||
| Section 3.01 | Exercise | 15 |
| Section 3.02 | Exercise Period | 16 |
| Section 3.03 | Expiration | 18 |
| Section 3.04 | Manner of Exercise | 18 |
| Section 3.05 | Issuance of Warrant Shares | 20 |
| Section 3.06 | Fractional Warrant Shares | 21 |
| Section 3.07 | Reservation of Warrant Shares | 22 |
| Section 3.08 | Automatic Net Exercise | 22 |
| Section 3.09 | Adjustments of Prices | 24 |
| ARTICLE IV | ||
| ADJUSTMENT AND NOTICE PROVISIONS | ||
| Section 4.01 | Adjustments | 25 |
| Section 4.02 | Calculation of Adjustments; Timing of Issuance of Additional Warrant Shares Upon Certain Adjustments; Adjustment Rules | 30 |
| Section 4.03 | Business Combinations and Reorganizations | 31 |
| Section 4.04 | Notice of Adjustments | 31 |
| Section 4.05 | Adjustment to Warrant Certificate | 32 |
| Section 4.06 | Amendments. | 32 |
i
| ARTICLE V | ||
| REGISTRATION OF WARRANT SHARES | ||
| Section 5.01 | Effectiveness of Registration Statement | 34 |
| Section 5.02 | Suspension | 34 |
| Section 5.03 | Expenses | 34 |
| ARTICLE VI | ||
| WARRANT AGENT | ||
| Section 6.01 | Appointment of Warrant Agent | 35 |
| Section 6.02 | Rights and Duties of Warrant Agent | 35 |
| Section 6.03 | Individual Rights of Warrant Agent | 36 |
| Section 6.04 | Warrant Agent’s Disclaimer | 37 |
| Section 6.05 | Compensation and Indemnity | 37 |
| Section 6.06 | Successor Warrant Agent | 38 |
| Section 6.07 | Bank Accounts | 39 |
| Section 6.08 | Delivery of Warrant Exercise Price | 39 |
| Section 6.09 | Further Assurances | 39 |
| Section 6.10 | Force Majeure | 40 |
| Section 6.11 | Confidentiality | 40 |
| ARTICLE VII | ||
| MISCELLANEOUS | ||
| Section 7.01 | Persons Benefiting | 40 |
| Section 7.02 | Rights of Holders | 40 |
| Section 7.03 | Notices | 41 |
| Section 7.04 | Governing Law | 42 |
| Section 7.05 | Successors | 42 |
| Section 7.06 | Counterparts | 42 |
| Section 7.07 | Severability | 43 |
| Section 7.08 | Withholding Rights | 43 |
| Section 7.09 | Calculations; Calculation Agent | 44 |
| Section 7.10 | Limited Responsibility of Calculation Agent and Independent Advisor | 44 |
| Section 7.11 | Entire Agreement | 44 |
EXHIBIT A Form of Warrant
EXHIBIT B Protocol for Exercise of Warrants with Designated Notes.
EXHIBIT C Accrued Interest Amount in respect of Designated Notes (Electronic Exercise) Surrender Dates
ii
WARRANT AGREEMENT, dated as of November 18, 2026 (this “Agreement”), between Enovix Corporation, a corporation incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company N.A., a federally chartered trust company, collectively, as Warrant Agent (the “Warrant Agent”) (each a “Party” and collectively, the “Parties”).
The Board of Directors has declared a dividend distribution (the “Warrant Distribution”) to the holders of record of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and the Other Eligible Recipients, as of the Close of Business on November 13, 2026 (such date and time, the “Distribution Record Date”), in the form of warrants to purchase shares of Common Stock. The Company desires to issue the warrants on the terms and conditions described herein (the “Warrants”) in satisfaction of the Warrant Distribution. The Warrants will be issued on or about November 18, 2026 (the date of the actual distribution, the “Issue Date”).
The Company desires the Warrant Agent to act on behalf of the Company in connection with the issuance, registration, transfer, exchange, exercise, redemption and cancellation of the Warrants as provided herein, and the Warrant Agent is willing to so act.
Each Party hereto agrees for the benefit of the other Party and for the equal and ratable benefit of the registered holders of the Warrants (the “Holders”):
Article I
Definitions
Section 1.01 Definitions.
“2028 Indenture” means the indenture for the 2028 Notes, dated as of April 20, 2023, by and among the Company and U.S. Bank Trust Company, National Association, as trustee.
“2030 Indenture” means the indenture for the 2030 Notes, dated as of September 15, 2025, by and among the Company and U.S. Bank Trust Company, National Association, as trustee.
“2028 Notes” means the Company’s 3.00% Convertible Senior Notes due 2028 (CUSIP#: 293594AC1).
“2030 Notes” means the Company’s 4.75% Convertible Senior Notes due 2030 (CUSIP#: 293594AF4).
“Accrued Interest Amount” means, in respect of any Designated Notes (Electronic Exercise) Surrender Date, the amount per $1,000 in principal amount of the relevant series of Designated Notes set forth for such Designated Notes (Electronic Exercise) Surrender Date (i) in Exhibit C or (ii) if such series of Designated Notes are not the 2028 Notes, in the public announcement required to be published at the time of the designation of such series of Designated Notes in accordance with the definition of “Designated Notes.”
“Affiliate” of any Person means any other Person that, directly or indirectly, is in control of, is controlled by or is under common control with such Person. For purposes hereof, “control” of a Person means the power, direct or indirect, to direct or cause the direction of the management and policies of such Person whether by contract or otherwise.
1
“Board of Directors” means the Board of Directors of the Company or any committee thereof duly authorized to act on behalf of such Board of Directors.
“Business Combination” means a merger, consolidation, amalgamation, statutory share exchange or similar transaction that requires the approval of the Company’s shareholders.
“Business Day” means a day that is not (i) a Saturday, (ii) a Sunday, or (iii) a day on which banking institutions are allowed by law, regulation or executive order to be closed in the State of New York.
“Calculation Agent” means Conv-Ex Advisors Limited, or such successor Person as may be appointed by the Company to serve as calculation agent for the Warrants.
“Capital Stock” means (i) with respect to any Person that is a corporation or company, any and all shares, interests, participations or other equivalents (however designated) of capital or capital stock of such Person and (ii) with respect to any Person that is not a corporation or company, any and all partnership or other equity interests of such Person.
“Close of Business” means 5:00 p.m., New York City time.
“Convertible Notes” means the 2028 Notes and the 2030 Notes.
“Daily VWAP” of a share of Common Stock (or a Warrant or other security) on any date of determination means, (i) in the case of a share of Common Stock, for any day on which trading in the Common Stock generally occurs on the Exchange (or, if the Common Stock is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock on such day), the per-share volume-weighted average price in the consolidated tape system during Regular Market Hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVX US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day, (ii) in the case of a Warrant, for any day on which trading in the Warrant generally occurs on the Exchange (or, if the Warrants are not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Warrants on such day), the per-warrant volume-weighted average price in the consolidated tape system during Regular Market Hours as displayed under the headings “Calculation: Bloomberg” and “VWAP” on Bloomberg page “ENVXW US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day and (iii) in the case of any other security, for any day on which trading in such security generally occurs on the Exchange (or, if such security is not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of such security on such day), the per-share volume-weighted average price in the consolidated tape system during Regular Market Hours as displayed on Bloomberg page “AQR” for such security in respect of such day. If such information is not so available for the Common Stock (or Warrant or such other security, as the case may be), the Daily VWAP on such date shall be the Last Reported Sale Price for the Common Stock (or Warrant or such other security, as the case may be) on such day.
“Daily Warrant VWAP Volume” means, for any day on which trading in the Warrants generally occurs on the Exchange (or, if the Warrants are not listed on the Exchange, the U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Warrants on such day), the trading volume in the consolidated tape system during Regular Market Hours as displayed under the headings “Calculation: Bloomberg” and “Volume” on Bloomberg page “ENVXW US Equity AQR” (or its equivalent successor if such page is not available) in respect of such day.
2
“Definitive Warrant” means a Warrant Certificate in definitive form that is not deposited with the Depositary or with the Warrant Agent as the Warrant Custodian.
“Depositary” means The Depository Trust Company, its nominees, and their respective successors.
“Designated Notes” means, collectively, any of the issued and outstanding notes of the Company, as designated or undesignated by the Company from time to time by giving notice thereof to the Holders (by making a public announcement thereof, which public announcement may be by issuance of a press release), the Warrant Agent and the Calculation Agent; provided that any designation by the Company of a particular series of notes as “Designated Notes” shall retain such designation for a minimum of 20 consecutive Business Days from (and including) the date of publication of such notice. The Company may also elect, in its sole and absolute discretion, to remove one or more series of its notes from being “Designated Notes,” including the right to remove all series of its notes from being “Designated Notes,” but such removal shall only be effective 20 consecutive Business Days from (and including) the date of publication of such notice. The Company initially designates the 2028 Notes as Designated Notes.
“DWAC” has the meaning set forth in Exhibit B.
“Early Expiration Price Condition” means (i) the occurrence of the first 30 consecutive Trading Day period that includes 20 Qualifying Trading Days (whether or not consecutive), the first of which 20 Qualifying Trading Days must fall on or after the first Trading Day immediately following the Issue Date or (ii) in the event of any Alternate Early Expiration Date Annulment, the occurrence of the first 30 consecutive Trading Day period commencing after the Alternate Early Expiration Date in respect of which such Alternate Early Expiration Date Annulment occurred that includes 20 Qualifying Trading Days (whether or not consecutive).
“Early Expiration Price Condition Date” means the last of the 20 Qualifying Trading Days (whether or not consecutive) to occur in the Reference Period.
“Early Expiration Trigger Price” means initially $3.30, subject to adjustment concurrently with (a) any adjustment in accordance with Section 4.01 or (b) amendment in accordance with Section 4.06 to the Warrant Exercise Rate or amendment to the Warrant Exercise Price in accordance with Section 4.06. In any adjustment or amendment to the Warrant Exercise Rate, the adjusted Early Expiration Trigger Price shall equal the product (rounded to the nearest whole multiple of $0.0001 (with $0.00005 being rounded upwards)) of (i) the Early Expiration Trigger Price applicable immediately prior to such adjustment and (ii) a fraction, the numerator of which is the Warrant Exercise Rate in effect immediately prior to such adjustment or amendment (as applicable) and the denominator of which is the Warrant Exercise Rate as so adjusted or amended (as applicable), all as determined by the Calculation Agent. In any amendment to the Warrant Exercise Price, the adjusted Early Expiration Trigger Price shall equal the product (rounded to the nearest whole multiple of $0.0001 (with $0.00005 being rounded upwards)) of (i) the Early Expiration Trigger Price applicable immediately prior to such adjustment and (ii) a fraction, the numerator of which is the Warrant Exercise Price as so amended and the denominator of which is the Warrant Exercise Price in effect immediately prior to such amendment, all as determined by the Calculation Agent.
“Electronic Exercise” has the meaning set forth in Exhibit B.
3
“Ex-Date” means the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of shares of Common Stock on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market. For the avoidance of doubt, any alternative trading convention on the applicable exchange or market in respect of the Common Stock under a separate ticker symbol or CUSIP number will not be considered “regular way” for this purpose.
“Exchange” means the Nasdaq Global Select Market.
“Exchange Act” means the U.S. Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as they may be amended from time to time.
“Fair Market Value” means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board of Directors, acting in good faith.
“Indentures” means the 2028 Indenture and the 2030 Indenture.
“Independent Advisor” means a nationally recognized independent investment banking firm or financial advisor with appropriate expertise (which may include the person acting as the Calculation Agent or any affiliate thereof) retained by the Company at its own expense.
“Last Reported Sale Price” means, with respect to the Common Stock (or Warrant or other security), on any given day, the last sale price, regular way, or, in case no such sale takes place on such day, the average of the last bid price and last ask price (or, if more than one in either case, the arithmetic average of the average last bid prices and the average last ask prices), regular way, of the Common Stock (or Warrant or such other security, as the case may be) as reported in composite transactions for the Exchange on such day during Regular Market Hours, provided that if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange on any date of determination, the Last Reported Sale Price of the Common Stock (or Warrant or such other security, as the case may be) on such date of determination means the closing sale price as reported in the composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock (or Warrant or such other security, as the case may be) is so listed or quoted, or, if no closing sale price is reported, the last reported sale price during Regular Market Hours on the principal U.S. national or regional securities exchange on which the Common Stock (or Warrant or such other security, as the case may be) is so listed or quoted, or, if the Common Stock (or Warrant or such other security, as the case may be) is not so listed or quoted on a U.S. national or regional securities exchange, the last quoted bid price for the Common Stock (or Warrant or such other security, as the case may be) in the over-the-counter market as reported by OTC Markets Group Inc. or a similar organization, or, if that bid price is not available, the Last Reported Sale Price of the Common Stock (or Warrant or such other security, as the case may be) on that date shall mean the Fair Market Value per share of Common Stock (or Warrant or such other security, as the case may be) as of such day.
“Market Disruption Event” means, with respect to any date, (A) the failure by the principal U.S. national or regional securities exchange on which the Common Stock is then listed, or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, the principal other market on which the Common Stock is then admitted for trading, to open for trading during its regular trading session (disregarding any after-hours trading) on such date; or (B) the occurrence or existence, for more than one half hour period in the aggregate, of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in the Common Stock, and such suspension or limitation occurs or exists at any time before 1:00 p.m., New York City time, on such date; provided, however, that a restriction on trading imposed solely by Rule 201 of Regulation SHO promulgated under the Exchange Act (as in effect on the date of this Agreement) shall not constitute a “Market Disruption Event.”
4
“Note Conversion Amount” means, (x) in respect of the 2028 Notes, a number of shares of Common Stock equal to the product of (i) the Conversion Rate (as defined in the 2028 Indenture) in effect on the Distribution Record Date; and (ii) the aggregate number of 2028 Notes (expressed as the principal amount thereof divided by $1,000) held by the holders of 2028 Notes on such date and (y) in respect of the 2030 Notes, a number of shares of Common Stock equal to the product of (i) the Conversion Rate (as defined in the 2030 Indenture) in effect on the Distribution Record Date; and (ii) the aggregate number of 2030 Notes (expressed as the principal amount thereof divided by $1,000) held by the holders of 2030 Notes on such date.
“Officer” means, with respect to the Company, the Chief Executive Officer, the President, the Chief Financial Officer, or the Chief Legal Officer and Corporate Secretary of the Company or, with respect to any other Person, the Chief Executive Officer, the President, the Chief Financial Officer, any Vice President, the Treasurer, any Assistant Treasurer, or the Secretary or an Assistant Secretary of such Person.
“Other Eligible Recipient” means a holder of record of the Convertible Notes as of the Distribution Record Date.
“Person” means any individual, corporation, partnership, joint venture, limited liability company, association, joint-stock company, trust, unincorporated organization, government or any agency or political subdivision thereof, or any other entity.
“Qualifying Trading Day” means any S+W Trading Day on which the Daily VWAP of a share of Common Stock is at least equal to the Early Expiration Trigger Price in effect on the last day of the Reference Period (or, for the purposes of Section 3.02(d), in effect on such S+W Trading Day). For purposes of this definition, the Daily VWAP shall not be adjusted or otherwise modified to take into account any adjustment in accordance with Section 4.01 or amendment in accordance with Section 4.06 to the Warrant Exercise Rate or amendment in accordance with Section 4.06 to the Warrant Exercise Price giving rise to an adjustment to the Early Expiration Trigger Price (pursuant to the definition thereof), whether or not such adjustment to the Early Expiration Trigger Price is in effect on the last day of the Reference Period (and, in the case of an adjustment to the Warrant Exercise Rate giving rise to an adjustment to the Early Expiration Trigger Price, whether or not the Ex-Date (or, in the case of any subdivision, combination, consolidation or reclassification of the issued and outstanding shares of Common Stock, the effective date) of the relevant Warrant Exercise Rate adjustment event occurs before, on or after the date in respect of which such Daily VWAP is being determined).
“Record Date” means, for the purposes of Sections 4.01 and 4.02, with respect to any dividend, distribution or other transaction or event in which the holders of the Common Stock have the right to receive any cash, securities or other property or in which the Common Stock (or other applicable security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock entitled to receive such cash, securities or other property (whether such date is fixed by the Board of Directors or by statute, contract or otherwise).
“Reference Period” means, as applicable, the 30 consecutive Trading Day period referred to in clause (i) or clause (ii) of the definition of Early Expiration Price Condition.
“Regular Market Hours” means the market hours on the Exchange or the principal U.S. national or regional securities exchange or association or over-the-counter market on which the Common Stock or Warrants (or other security, as the case may be) is listed or quoted that most closely corresponds to the period from 9:30 a.m. New York City time to 4:00 p.m. New York City time (e.g., “Regular Market Hours” on the Exchange and “Core Session” hours on the New York Stock Exchange).
5
“Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange on which the Common Stock is listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, the principal market on which the Common Stock is admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day.
“SEC” means the U.S. Securities and Exchange Commission.
“Securities Act” means the U.S. Securities Act of 1933 and the rules and regulations promulgated thereunder, as they may be amended from time to time.
“S+W Trading Day” means any day which is a Trading Day for both the Common Stock and the Warrant.
“Trading Day” for the Common Stock (or Warrant or other security) means a day on which the Common Stock (or Warrant or other security, as the case may be) (i) at the close of regular way trading (not including after-hours or extended market trading) is not suspended from trading on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, any U.S. national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be) at the Close of Business, and (ii) has traded at least once regular way on the Exchange or, if the Common Stock (or Warrant or such other security, as the case may be) is not listed on the Exchange, such other U.S. national securities exchange or association or over-the-counter market that is the primary market for the trading of the Common Stock (or Warrant or such other security, as the case may be); provided that if the Common Stock (or Warrant or such other security, as the case may be) is not so listed or traded, “Trading Day” means a Business Day, and provided further that unless specified to be for a Warrant or other security, “Trading Day” means a Trading Day for the Common Stock.
“Warrant Certificate” means any Global Warrant or Definitive Warrant issued by the Company under this Agreement.
“Warrant Custodian” means the custodian with respect to a Global Warrant (as appointed by the Depositary) or any successor Person thereto.
“Warrant Exercise Rate” means initially one (1) share of Common Stock, subject to adjustment in accordance with Section 4.01 from time to time or amendment in accordance with Section 4.06 from time to time.
“Warrant Shares” means the shares of Common Stock issuable on exercise of any Warrants.
“Whole Number” means any non-negative number, including zero, that is not a fraction or decimal.
6
Section 1.02 Other Definitions.
| Term | Defined in Section | |
| Additional Price Condition | 3.02(e) | |
| Agent Members | 2.01(c)(ii) | |
| Agreement | Preamble | |
| Alternate Early Expiration Date | 3.02(d) | |
| Alternate Early Expiration Date Annulment | 3.02(f) | |
| Automatic Net Exercise | 3.08(a) | |
| Automatic Net Exercise Calculation Period | 3.08(b) | |
| Automatic Net Exercise Holders | 3.08(a) | |
| Automatic Net Exercise Shares per Warrant | 3.08(b) | |
| Common Stock | Recitals | |
| Common Stock Shelf Registration Statement | 5.01 | |
| Company | Preamble | |
| Computershare | Preamble | |
| Designated Notes (Electronic Exercise) Surrender Date | 3.04(c) | |
| Distribution Record Date | Recitals | |
| DN Warrant Exercise Price | 3.01(a) | |
| Early Expiration Date | 3.02(b) | |
| Early Expiration Price Condition Notice | 3.02(c) | |
| Eligible Trading Day | 3.08(b) | |
| Exercise Date | 3.04(a) | |
| Exercise Notice | 3.04(a) | |
| Exercise Period | 3.02(g) | |
| Exercise Request Date | 3.04(a) | |
| Exercise Suspension Period | 5.01 | |
| Expiration Date | 3.02(b) | |
| Funds | 6.07 | |
| Global Warrant | 2.01(a)(iii) | |
| Holders | Recitals | |
| Initial Warrants | 2.01(a)(1) | |
| Issue Date | Recitals | |
| Losses | 6.05(b) | |
| Moody’s | 6.07 | |
| Parties | Preamble | |
| Party | Preamble | |
| 2.02 | ||
| Permitted Transfer | 3.08(a) | |
| S&P | 6.07 | |
| Scheduled Early Expiration Date | 3.02(b) | |
| Scheduled Expiration Date | 3.02(b) | |
| Spin-Off | 4.01(c)(ii) | |
| Stock Transfer Agent | 3.05(a) | |
| Unit of Reference Property | 4.03 | |
| Valuation Period | 4.01(c)(ii) | |
| Valuation Trading Day | 4.01(c)(ii) | |
| Warrant Agent | Preamble | |
| Warrant Distribution | Recitals | |
| Warrant Exercise Price | 3.01(a) | |
| Warrant Register | 2.03 | |
| Warrants | Recitals |
7
Section 1.03 Rules of Construction. Unless the text or context otherwise requires:
(a) a defined term has the meaning assigned to it herein;
(b) an accounting term not otherwise defined has the meaning assigned to it in accordance with U.S. generally accepted accounting principles as in effect from time to time;
(c) “including” means including, without limitation;
(d) words in the singular include the plural and words in the plural include the singular;
(e) references to any statute, rule, standard, regulation or other law include a reference to (x) the corresponding rules and regulations and (y) each of them as amended, modified, supplemented, consolidated, replaced or rewritten from time to time; and
(f) headings to Articles, Sections and Sub-Sections in this Agreement are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.
Article II
Form of Warrant; Beneficial Interests
Section 2.01 Issuance and Registration.
(a) Warrants.
(i) The Warrants shall initially be issued as follows (the “Initial Warrants”) to:
(1) the registered holders of shares of Common Stock as of the Distribution Record Date, as reflected in the Company’s direct registration system for the Common Stock, one Warrant for each four shares of Common Stock held by such registered holder as of the Distribution Record Date;
(2) the registered holders of the 2028 Notes as of the Distribution Record Date as reflected in the Register (as defined in the 2028 Indenture), pursuant to Section 14.04 of the 2028 Indenture, without such holders having to convert their 2028 Notes, one Warrant for each four shares of Common Stock included in the Note Conversion Amount for the aggregate principal amount of 2028 Notes held by such holders on the Distribution Record Date; and
8
(3) the registered holders of the 2030 Notes as of the Distribution Record Date as reflected in the Register (as defined in the 2030 Indenture), pursuant to Section 14.04 of the 2030 Indenture, without such holders having to convert their 2030 Notes, one Warrant for each four shares of Common Stock included in the Note Conversion Amount for the aggregate principal amount of 2030 Notes held by such holders on the Distribution Record Date;
(ii) The Warrant Agent shall allocate the Warrants to, and register the Warrants in the names of, such registered holders in accordance with the Company’s direct registration system or the Warrant Agent’s other book-entry procedures pursuant to an allocation schedule approved by the Company, and in the case of the registered holders of Convertible Notes, in cooperation with the trustee under the applicable Indenture. Any Warrants registered through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures shall be issued in uncertificated form and shall not be represented by Warrant Certificates.
(iii) Notwithstanding the foregoing, some or all of the Warrants may, at initial issuance or any time thereafter, be represented by one or more permanent Global Warrants, in definitive, fully registered form with the global securities legend set forth in Exhibit A hereto (each, a “Global Warrant”). Any such Global Warrant shall be deposited on behalf of the relevant Holders with the Warrant Agent, as custodian for the Depositary (or with such other custodian as the Depositary may direct), registered in the name of the Depositary or a nominee of the Depositary, and duly executed by the Company and countersigned by the Warrant Agent as hereinafter provided.
(iv) The Company may, subject to the provisions of this Agreement, issue additional Warrants with the same terms as the Initial Warrants, which additional Warrants will, subject to the foregoing, be considered to be part of the same series of, and rank equally and ratably with all other, Warrants issued under this Agreement; provided, however, that if any such additional Warrants are not fungible, for federal securities laws purposes, with other Warrants issued under this Agreement and assigned a CUSIP number, then such additional Warrants will be identified by a separate CUSIP number or by no CUSIP number. All Warrants issued pursuant to this Agreement will be equally and ratably entitled to the benefits of this Agreement, without preference or priority.
(b) Definitive Warrants. Holders of Warrants or holders of beneficial interests in any Global Warrant will not be entitled to physical delivery of Definitive Warrants (except as provided in Section 2.05).
9
(c) Procedures for Global Warrants. This Section 2.01(c) shall apply only to any Global Warrant deposited with or on behalf of the Depositary.
(i) If any Warrants are to be represented by a Global Warrant, then the Company shall execute and the Warrant Agent shall, in accordance with Section 2.02, countersign and deliver initially one or more Global Warrants that (a) shall be registered in the name of the Depositary for such Global Warrant or Global Warrants or of the nominee of the Depositary and (b) shall be delivered by the Warrant Agent to the Depositary or pursuant to the Depositary’s instructions or held by the Warrant Agent as custodian for the Depositary.
(ii) Members of, or participants in, the Depositary (“Agent Members”) shall have no rights under this Agreement with respect to any Global Warrant held on their behalf by the Depositary or by the Warrant Agent as the custodian of the Depositary or under such Global Warrant, and the Depositary may be treated by the Company, the Warrant Agent and any agent of the Company or the Warrant Agent as the absolute owner of such Global Warrant for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Warrant Agent or any agent of the Company or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by the Depositary, or impair, as between the Depositary and its Agent Members, the operation of customary practices of the Depositary governing the exercise of the rights of a holder of a beneficial interest in any Global Warrant.
(d) No Fractional Warrants. The Company shall not issue fractional Warrants or distribute Warrant Certificates which evidence fractional Warrants. If any fractional Warrant would otherwise be required to be issued or distributed pursuant to the Warrant Distribution, the Company or the Warrant Agent, as applicable, to the extent reasonably practicable, shall first aggregate the total number of Warrants to be issued to the relevant holder of Common Stock or Other Eligible Recipient and then round down the total number to the nearest Whole Number and no cash or other adjustment will be made in lieu of the fraction of a Warrant so rounded down.
Section 2.02 Warrant Certificates. If any Warrant Certificates are issued hereunder, then at least one Officer shall sign such Warrant Certificates for the Company by manual, facsimile or portable document format (“PDF”) signature or by means of other electronic transmission.
(a) If an Officer whose signature is on a Warrant Certificate no longer holds that office at the time the Warrant Agent countersigns the Warrant Certificate, the Warrants evidenced by such Warrant Certificate shall be valid, nevertheless.
10
(b) At any time and from time to time after the execution of this Agreement, the Warrant Agent shall, upon receipt of a written order of the Company signed by an Officer of the Company, countersign, either by manual, facsimile, PDF signature or by means of other electronic transmission, and issue a Warrant Certificate evidencing the number of Warrants specified in such order. Such order shall specify the number of Warrants to be evidenced on the Warrant Certificate to be countersigned, the date on which such Warrant Certificate is to be countersigned, whether such Warrant Certificate is to be a Global Warrant or a Definitive Warrant, and the number of Warrants then authorized. Each Warrant Certificate shall be dated the date of its countersignature.
(c) The Warrants (whether or not evidenced by a Warrant Certificate) shall not be valid until registered on the Warrant Register.
Section 2.03 Warrant Register. The Warrants shall be issued in registered form only. Upon the receipt of all relevant information from the Company or its agents, the Warrant Agent shall keep a register (the “Warrant Register”) of the Warrants (and Warrant Certificates, if applicable) and of their transfer and exchange. The Warrant Register shall show the names and addresses of the respective Holders and the date and number of Warrants owned by such Holders (as evidenced on the face of each of the Warrant Certificates, if applicable). The Holder of any Global Warrant will be the Depositary or a nominee in whose name the Global Warrant is registered.
The Company and the Warrant Agent may deem and treat the Person in whose name the Warrants are registered in the Warrant Register as the absolute owner of such Warrants for all purposes and regardless of any notice to the contrary.
Section 2.04 Transfer and Exchange.
(a) Transfer and Exchange of Warrants.
(i) The transfer and exchange of Warrants or beneficial interests therein shall be effected through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures and, in the case of any Global Warrants, the Depositary, in each case in accordance with this Agreement and the procedures of the Warrant Agent and, as applicable, the Depositary therefor. The Company may instruct the Warrant Agent from time to time that Warrants held by a member of the Board of Directors, an Officer of the Company or an Affiliate of the Company are subject to restrictions on transfers or exchanges related to compliance with applicable securities laws, in which case the Warrant Agent shall not permit the transfer or exchange of such Warrants without the consent of the Company.
(ii) Except as set forth in Section 2.04(a)(iii), a Global Warrant may only be transferred as a whole, and not in part, and only by (x) the Depositary to a nominee of the Depositary, (y) a nominee of the Depositary to the Depositary or another nominee of the Depositary or (z) the Depositary or any such nominee to a successor Depositary or its nominee.
11
(iii) In the event that a Global Warrant is exchanged and transferred for Definitive Warrants pursuant to Section 2.05, such Warrants may be exchanged only in accordance with such procedures as are substantially consistent with the provisions of this Section 2.04 and such other procedures as may from time to time be adopted by the Company.
(iv) The Warrant Agent may register the transfer of any Definitive Warrant upon written request of the Holder delivered to the Warrant Agent and surrender of the Warrant Certificates to be transferred, split up, combined or exchanged, together with the form of assignment and certificate duly executed and properly completed and such other documentation that the Company or the Warrant Agent may reasonably request, at the office of the Warrant Agent designated for such purpose. Any requested transfer of Warrants shall be accompanied by reasonable evidence of authority of the party making such request, which evidence shall include a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association. Upon any such transfer, one or more new Definitive Warrants representing an equal aggregate number of Definitive Warrants shall be issued and the transferred certificate shall be canceled.
(b) Cancellation or Adjustment of Global Warrant. At such time as all beneficial interests in a Global Warrant have been exchanged for Definitive Warrants, redeemed, repurchased or canceled, such Global Warrant shall be returned to the Depositary for cancellation or retained and canceled by the Warrant Agent. At any time prior to such cancellation, if any beneficial interest in a Global Warrant is exchanged for Definitive Warrants, repurchased or canceled, the number of Warrants represented by such Global Warrant shall be reduced and an adjustment shall be made on the books and records of the Warrant Agent (if it is then the Warrant Custodian for such Global Warrant) with respect to such Global Warrant, by the Warrant Agent, to reflect such reduction.
(c) Obligations with Respect to Transfers and Exchanges of Warrants.
(i) To permit registrations of transfers and exchanges, the Company shall execute and the Warrant Agent shall countersign, by either manual, facsimile or PDF signature or by means of other electronic transmission, any Global Warrants and Definitive Warrants, if applicable, as required subject to the provisions of Section 2.02 and this Section 2.04.
(ii) No service charge shall be made for any registration of transfer or exchange. Any transfer, tax, assessments, or similar governmental charge payable in connection with any registration of transfer or exchange shall be paid by the Holder.
(iii) The Company may require payment from the Holder of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer, split up, combination or exchange of Warrants. The Warrant Agent shall not have any duty or obligation to take any action under any section of this Agreement or any Warrant that requires the payment of taxes and/or charges unless and until the Warrant Agent is reasonably satisfied that all such payments have been made.
12
(iv) Prior to the due presentation for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the Person in whose name Warrants are registered as the absolute owner of such Warrants, and neither the Company nor the Warrant Agent shall be affected by notice to the contrary.
(v) All Warrants issued upon any transfer or exchange pursuant to the terms of this Agreement shall be valid obligations of the Company, entitled to the same benefits under this Agreement as the Warrants surrendered upon such transfer or exchange.
(d) No Obligation of the Warrant Agent. The Warrant Agent shall have no responsibility or obligation to any beneficial owner of a Global Warrant, an Agent Member or other Person with respect to the accuracy of the records of the Depositary or its nominee or of any participant or member thereof, with respect to any ownership interest in the Warrants or with respect to the delivery to any participant, member, beneficial owner or other Person (other than the Depositary) of any notice, or the payment of any amount, under or with respect to such Warrants. All notices and communications to be given to the Holders and all payments to be made to the Holders under the Warrants shall be given or made only to or upon the order of the registered Holders (which shall be the Depositary or its nominee in the case of a Global Warrant). The rights of beneficial owners in any Global Warrant shall be exercised only through the Depositary subject to the applicable rules and procedures of the Depositary. The Warrant Agent may rely and shall be fully protected in relying upon information furnished by the Depositary with respect to its members, participants and any beneficial owners.
Section 2.05 Definitive Warrants.
(a) Subject to Section 2.05(e), beneficial interests in a Global Warrant deposited with the Depositary or with the Warrant Agent as custodian shall be transferred to the beneficial owners thereof in the form of Definitive Warrants in a number equal to the number of Warrants represented by such Global Warrant, in exchange for such Global Warrant, only if such transfer complies with Section 2.04 and (i) the Depositary notifies the Company that it is unwilling or unable to continue as depositary for such Global Warrant or if at any time the Depositary ceases to be a “clearing agency” registered under the Exchange Act and, in each such case, a successor depositary is not appointed by the Company within 90 days of such notice, or (ii) the Company, in its sole discretion, notifies the Warrant Agent in writing that it elects to cause the issuance of Definitive Warrants under this Agreement. In such event, the transfer, exchange or exercise of the Warrants shall be conducted in accordance with the customary procedures of the Warrant Agent.
(b) Any Global Warrant that is transferable to the beneficial owners thereof pursuant to this Section 2.05 shall be surrendered by the Depositary to the Warrant Agent, to be so transferred, in whole or from time to time in part, without charge, and the Warrant Agent shall countersign, by either manual, facsimile or PDF signature or by means of other electronic transmission, and deliver to each beneficial owner in the name of such beneficial owner, upon such transfer of each portion of such Global Warrant, Definitive Warrants evidencing a number of Warrants equivalent to such beneficial owner’s beneficial interest in the Global Warrant. The Warrant Agent shall register such transfer in the Warrant Register, and upon such transfer the surrendered Global Warrant shall be canceled by the Warrant Agent. Any such Definitive Warrants shall bear such restrictive legends as the Company may instruct.
(c) Subject to the provisions of Section 2.05(b), the registered Holder of a Global Warrant may grant proxies and otherwise authorize any Person, including Agent Members and Persons that may hold interests through Agent Members, to take any action that a Holder is entitled to take under this Agreement or the Warrants.
13
(d) In the event of the occurrence of either of the events specified in Section 2.05(a), the Company will promptly make available to the Warrant Agent a reasonable supply of Definitive Warrants in definitive, fully registered form.
(e) The Depositary shall notify the Warrant Agent of the names and the amounts in which the Definitive Warrants will be issued. Neither the Company nor the Warrant Agent will be liable or responsible for any names or any amounts provided by the Depositary.
(f) Notwithstanding the foregoing, in lieu of issuing a Definitive Warrant to any Person, the Warrant Agent may, upon the Company’s instruction, register Warrants in the name of such Person through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures.
Section 2.06 Replacement Certificates. If a mutilated Warrant Certificate is surrendered to the Warrant Agent or if the Holder of a Warrant Certificate provides proof reasonably satisfactory to the Company and the Warrant Agent that the Warrant Certificate has been lost, destroyed or wrongfully taken, the Company shall issue and the Warrant Agent shall countersign, by either manual, facsimile or PDF signature or by means of other electronic transmission, a replacement Warrant Certificate representing an equivalent number of Warrants, if the reasonable requirements of the Warrant Agent are met and absent notice to the Warrant Agent that such certificates have been acquired by a bona fide purchaser. Such Holder shall furnish an open penalty surety bond sufficient in the judgment of the Company and the Warrant Agent to protect the Company and the Warrant Agent from any loss that either of them may suffer if a Warrant Certificate is replaced. The Warrant Agent may, at its option, issue replacement Warrants for mutilated certificates upon presentation thereof without such surety bond. The Company and the Warrant Agent may charge the Holder for their respective expenses in replacing a Warrant Certificate. Every replacement Warrant Certificate evidences an additional obligation of the Company.
Section 2.07 Outstanding Warrants. All Warrants evidenced as outstanding in the Warrant Register shall be deemed to be outstanding for purposes of this Agreement (which, in the case of Warrants represented by Warrant Certificates, shall include all Warrant Certificates countersigned by the Warrant Agent excluding those canceled by it and those delivered to it for cancellation). A Warrant does not cease to be outstanding because an Affiliate of the Company holds the Warrant. A Warrant ceases to be outstanding if the Company holds the Warrant.
If a Warrant Certificate is replaced pursuant to Section 2.06, the Warrants evidenced thereby cease to be outstanding unless the Warrant Agent and the Company receive proof satisfactory to them that the replaced Warrant Certificate is held by a protected purchaser (as defined for purposes of the Delaware Uniform Commercial Code).
Section 2.08 Cancellation. In the event the Company shall purchase or otherwise acquire Definitive Warrants, the Company may, at its option, deliver the same to the Warrant Agent for cancellation.
The Warrant Agent and no one else shall cancel all Warrant Certificates surrendered for transfer, exchange, replacement, exercise or cancellation. The Company may not issue new Warrant Certificates to replace Warrant Certificates to the extent they evidence Warrants which have been exercised or Warrants which the Company has canceled.
14
Section 2.09 CUSIP Numbers. The Company has assigned a “CUSIP” number in connection with the issuance of the Warrants and the Warrant Agent may use such “CUSIP” number in notices as a convenience to the Holders; provided, however, that any such notice shall state that no representation is made as to the correctness of such numbers either as printed on the Warrant Certificates or as contained in any notice and that reliance may be placed only on the other identification numbers printed on the Warrant Certificates.
Article III
Exercise Terms
Section 3.01 Exercise.
(a) Each Warrant shall entitle the Holder thereof to purchase, during the Exercise Period, for each Warrant evidenced thereby, a number of shares of Common Stock equal to the Warrant Exercise Rate in effect immediately prior to the Close of Business on the relevant Exercise Date, subject to Section 3.06, at an exercise price equal to $3.00 per Warrant (subject to amendment from time to time in accordance with Section 4.06, the “Warrant Exercise Price”), payable in cash. Alternatively, at the Holder’s option, if there are any Designated Notes as of the relevant Exercise Request Date, a Holder may exercise Warrants by delivering Designated Notes in an amount equal to $1,000 principal amount of Designated Notes to exercise up to (or, in the case of an Electronic Exercise, to exercise not more and not less than) 333 Warrants (subject to adjustment in accordance with Section 4.02(d), the “DN Warrant Exercise Price”) in the manner specified by, and subject to, Sections 3.04(a)(iii) and 3.04(c). Automatic Net Exercise of Warrants by Automatic Net Exercise Holders is governed by Section 3.08. Holders may exercise all or a portion of their Warrants (provided always that any such exercise shall be in respect of a Whole Number of Warrants) or choose not to exercise any Warrants at all, or may otherwise sell or transfer their Warrants, in each case, in their sole and absolute discretion (subject to the restrictions set forth in Section 3.08(a) in the case of the Automatic Net Exercise Holders).
(b) The number of shares of Common Stock issuable in respect of any exercise of Warrants represented by a Global Warrant shall be determined by the Depositary (or, as may be agreed from time to time between the Calculation Agent and the Company, the Calculation Agent) in accordance with this Agreement; provided that in the event the Company disagrees in good faith with any such calculation, the Company may make such calculation in good faith or appoint an Independent Advisor to make such calculation, and the Company’s (or, as the case may be, such Independent Advisor’s) calculation shall be determinative and final and binding on the Depositary, the Warrant Agent, the Calculation Agent, the Holders and (where such calculation is made by an Independent Advisor) the Company. Subject to Section 3.08(c) in the case of an Automatic Net Exercise, the number of shares of Common Stock issuable in respect of any exercise of Warrants represented through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures shall be determined by the Warrant Agent (or, as may be agreed from time to time between the Calculation Agent and the Company, the Calculation Agent) in accordance with this Agreement; provided that in the event the Company disagrees in good faith with any such calculation, the Company may make such calculation in good faith or appoint an Independent Advisor to make such calculation, and the Company’s (or, as the case may be, such Independent Advisor’s) calculation shall be determinative and final and binding on the Warrant Agent, the Calculation Agent, the Holders and (where such calculation is made by an Independent Advisor) the Company.
15
Section 3.02 Exercise Period.
(a) Subject to the terms and conditions set forth herein (including without limitation Section 3.04, Section 3.08 and Article V), the Warrants shall be exercisable at any time and from time to time on or after the Issue Date until the Close of Business on the Expiration Date. Notwithstanding the foregoing, the Holders will be able to exercise the Warrants only if (i) the Common Stock Shelf Registration Statement relating to the Warrant Shares is effective and neither the Exercise Request Date nor the Exercise Date falls in an Exercise Suspension Period and (ii) the Warrant Shares are qualified for sale or exempt from qualification under the applicable securities laws of the states or other jurisdictions in which such Holders reside, except as otherwise provided in Section 5.01. The Company may instruct the Warrant Agent in writing from time to time that Warrants held by a member of the Board of Directors, an Officer of the Company or an Affiliate of the Company are subject to further restrictions on exercise related to compliance with applicable securities laws, in which case the Warrant Agent shall not permit the exercise of such Warrants without the written consent of the Company.
(b) Subject to the terms and conditions set forth herein (including Section 3.04 and Article V), the Warrants will expire and cease to be exercisable at the Close of Business on the date (the “Expiration Date”) which is (i) April 28, 2028 (subject to amendment in accordance with Section 4.06, the “Scheduled Expiration Date”) or (ii) if the Early Expiration Price Condition occurs, the Early Expiration Date, where “Early Expiration Date” means either (x) the first Scheduled Trading Day immediately following the Early Expiration Price Condition Date (subject to Section 3.02(h)) (the “Scheduled Early Expiration Date”) or (y) if the Company elects to set an Alternate Early Expiration Date pursuant to Section 3.02(d), such Alternate Early Expiration Date (as may be subsequently adjusted pursuant to Section 3.02(e)), subject to Section 3.02(h).
(c) If the Early Expiration Price Condition Date occurs, the Company will make a public announcement to that effect by issuance of a press release (the “Early Expiration Price Condition Notice”) (and will give notice thereof to the Warrant Agent and the Calculation Agent) as promptly as practicable after the end of the Regular Market Hours on the Early Expiration Price Condition Date setting forth the Early Expiration Date.
(d) The Company may, in its sole discretion, elect to set the Early Expiration Date to be a Scheduled Trading Day falling after the Scheduled Early Expiration Date (any such Scheduled Trading Day, as such date may be subsequently adjusted pursuant to Section 3.02(e), an “Alternate Early Expiration Date”). Any such Alternate Early Expiration Date shall be specified in the Early Expiration Price Condition Notice, provided that such Alternate Early Expiration Date may be subsequently adjusted pursuant to Section 3.02(e). In order to exercise the right to set an Alternate Early Expiration Date, the Company shall, no later than the fifth Qualifying Trading Day (whether or not consecutive) occurring in any 20 consecutive Trading Day period ending on or before the next following Early Expiration Price Condition Date (if any), make a public announcement by issuance of a press release (and will give notice thereof to the Warrant Agent and the Calculation Agent) that the Company is reserving the right to set an Alternate Early Expiration Date in the event the Early Expiration Price Condition does occur.
16
(e) If the Company sets an Alternate Early Expiration Date:
(i) whether or not the Additional Price Condition (pursuant to Section 3.02(e)(ii)) in respect of such Alternate Early Expiration Date is met, the Company may, in its sole discretion, (a) postpone such Alternate Early Expiration Date to a new Alternate Early Expiration Date (which shall be a Scheduled Trading Day), and (b) postpone further (on one or more occasions) such Alternate Early Expiration Date to a new Alternate Early Expiration Date, provided that the Company makes a public announcement thereof by issuance of a press release (and gives notice thereof to the Warrant Agent and the Calculation Agent) published no later than as promptly as practicable after the end of the Regular Market Hours on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date to be so postponed; and
(ii) the expiration of the Warrants on any such Alternate Early Expiration Date (including any Alternate Early Expiration Date postponed in accordance with Section 3.02(e)(i)) shall be conditioned on, in respect of each of the two consecutive Scheduled Trading Days immediately preceding such Alternate Early Expiration Date, (i) no Market Disruption Event occurring on such Scheduled Trading Day and (ii) the Daily VWAP of a share of Common Stock on such Scheduled Trading Day being at least equal to the quotient of the Warrant Exercise Price divided by the Warrant Exercise Rate in effect on such Scheduled Trading Day (the “Additional Price Condition” in respect of such Alternate Early Expiration Date). As promptly as practicable after close of the Regular Market Hours on the Scheduled Trading Day immediately preceding the Alternate Early Expiration Date, the Company will make a public announcement by issuance of a press release (and will give notice thereof to the Warrant Agent and the Calculation Agent) as to whether the Additional Price Condition is met.
(f) If (i) the Additional Price Condition is not met in respect of any Alternate Early Expiration Date and (ii) the Company does not postpone such Alternate Early Expiration Date as set forth in Section 3.02(e)(i) (an “Alternate Early Expiration Date Annulment” in respect of such Alternate Early Expiration Date), the Expiration Date will remain the Scheduled Expiration Date unless another Early Expiration Price Condition Date subsequently occurs (subject to the terms and conditions set forth herein (including without limitation Section 3.04 and Section 5)).
(g) The “Exercise Period” is the period during which the Warrants are exercisable in accordance with and subject to the terms and conditions set forth herein (including this Section 3.02, Section 3.08, Section 4.06 and Article V).
(h) In the event that a Market Disruption Event occurs (i) on the first Scheduled Trading Day immediately following the Early Expiration Price Condition Date or (ii) if an Alternate Early Expiration Date is set by the Company, on such date, then the Company may set an Alternate Early Expiration Date whether or not it has complied with the condition described in the third sentence of Section 3.02(d) (or, in the case of an Alternate Early Expiration Date, with the provisions of Section 3.02(e)(i)) with respect to such Warrants.
17
Section 3.03 Expiration. A Warrant shall terminate and become void as of the earlier of (i) the Close of Business on the Expiration Date and (ii) the time such Warrant is exercised.
Section 3.04 Manner of Exercise.
(a) Subject to Sections 3.02(b), 3.03 and, in the case of an Automatic Net Exercise, 3.08, Warrants may be exercised by a Holder in full or in part, on any Business Day (each, an “Exercise Request Date”) falling in the Exercise Period, by, prior to the Close of Business on the Expiration Date:
(i) (x) delivery to the Warrant Agent at its office of the related Warrant Certificate, in the case of Definitive Warrants, (y) delivery of the Warrant through the procedures of the Warrant Agent in the case of Warrants represented through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures or (z) delivery of the Warrant through the systems of the Depositary using the DWAC system or Electronic Exercise, in the case of Global Warrants.
(ii) electronic delivery to the Warrant Agent of an election to purchase Warrant Shares in the applicable form included in Exhibit A (an “Exercise Notice”), duly completed and signed by the Holder; provided that if such delivery occurs on or after the Close of Business on such Business Day, it shall instead be deemed to have occurred on the immediately following Business Day; and
(iii) either, at the Holder’s election:
(1) payment in United States dollars by check payable to the order of the Company or the Warrant Agent or by wire transfer to the Company or the Warrant Agent of immediately available funds to an account of or for the benefit of the Company (as designated by the Company and available upon request from the Warrant Agent) in an amount equal to the Warrant Exercise Price multiplied by the number of Warrants so exercised; or
(2) if there are any Designated Notes as of the Exercise Request Date, surrendering to the Company one or more series of Designated Notes through the DWAC system or Electronic Exercise in principal amounts of $1,000 and integral multiples thereof (regardless of the then current market value of such Designated Notes, and disregarding any accrued but unpaid interest as of the applicable date of surrender (or any other date)), in an amount at least equal to the DN Warrant Exercise Price for the number of Warrants so exercised.
provided that (a) in no event will a Holder be entitled to interest accrued on Funds deposited with the Warrant Agent in respect of an exercise or attempted exercise of Warrants, (b) the Exercise Request Date shall be the first Business Day on which all of (i), (ii) and (iii) above have occurred (or deemed to have occurred), as determined by the Company in consultation with the Warrant Agent, and (c) notwithstanding anything to the contrary set forth herein, the Company may, in its sole and absolute discretion, from time to time offer Holders or their brokers the right to deliver a notice of guaranteed delivery on the Exercise Request Date with respect to Warrants or Designated Notes in order to satisfy the delivery requirements of clause (i) or (iii)(2) above as of the Exercise Request Date or the Exercise Date; and provided further that the date on which any Warrant shall be deemed to be exercised for the purposes of this Agreement shall be the Exercise Date in respect of the relevant Exercise Request Date for such exercise.
“Exercise Date” means (i) in respect of any Exercise Request Date in relation to any exercise of Warrants (A) which is an Electronic Exercise and (B) in respect of which the Warrant Exercise Price is paid using Designated Notes, the date falling on the earlier of (x) the Tuesday immediately following such Exercise Request Date (regardless of whether such Tuesday is a Business Day) or, if such Exercise Request Date falls on a Tuesday, such Tuesday and (y) the Expiration Date (provided always that such Exercise Request Date falls on or before such Expiration Date), or (ii) in respect of any Automatic Net Exercise, the Expiration Date, or (iii) in respect of any Exercise Request Date in relation to any other exercise of Warrants, such Exercise Request Date, provided, for the avoidance of doubt, that no Exercise Date shall occur after the Expiration Date.
18
(b) In the case of a Global Warrant, any Person with a beneficial interest in such Global Warrant shall effect compliance with the requirements in Section 3.04(a)(i), (ii) and (iii) above through the relevant Agent Member in accordance with the procedures of the Depositary, subject to Section 3.04(c) and with the protocol set forth in Exhibit B to this Agreement, or in accordance with such other procedures as shall be agreed by the Company and the Warrant Agent in writing. In the event of any material change to any delivery protocols, the Company will post a description of such updated protocols on its investor relations website and deliver notice of such updated protocols through the notices portal of the Depositary.
(c) In the case of Global Warrants or Designated Notes held through the Depositary, the surrendering to the Company of such Global Warrants and/or Designated Notes shall be subject to the Depositary’s applicable procedures and the relevant Holder effecting, or arranging for, the delivery or transfer of such Warrants or Designated Notes through the Depositary’s deposit and withdrawal at custodian (DWAC) system or through Electronic Exercise as described in Exhibit B. If a Holder delivers Warrants or Designated Notes through the DWAC system on or after 2:30 p.m. New York City time on a Business Day, such Warrants or Designated Notes will not be accepted, such delivery shall be deemed not to have occurred on such Business Day, and the Holder shall be required to re-deliver such Warrants or Designated Notes through the DWAC system on the following Business Day (provided that valid re-delivery is effective no later than the Close of Business on the Expiration Date). If a Holder delivers Warrants or Designated Notes through Electronic Exercise, submission and validation of the delivery of Warrants and Designated Notes shall occur on the weekly schedule specified in Exhibit B. Instructions received after the applicable weekly submission cutoff of 5:00 p.m. New York City time on Tuesdays shall be processed in the following weekly cycle (provided that valid delivery or re-delivery of such instructions is effective no later than the Close of Business on the Expiration Date). Incorrect, incomplete or unmatched instructions identified during weekly validation shall be rejected, and the Holder may correct and resubmit such instructions for processing in the next weekly cycle, (provided that valid resubmission of such instructions is effective no later than the Close of Business on the Expiration Date), in each case subject to any guaranteed delivery procedures that the Company may implement from time to time pursuant to this Agreement. The day on which the Designated Notes are deemed to be validly delivered through Electronic Exercise in accordance with the foregoing provisions shall be the “Designated Notes (Electronic Exercise) Surrender Date” in respect of such Designated Notes so delivered.
(d) If the principal amount of one or more series of Designated Notes surrendered to exercise Warrants is in excess of the principal amount required to be surrendered to pay the DN Warrant Exercise Price to exercise the number of Warrants so exercised, as determined by the Company in accordance with Section 3.04, the Company will only return such excess principal amount if and to the extent that (i) such excess can be returned in an authorized denomination of the Designated Notes that have been so surrendered and (ii) the remaining principal amount of the Designated Notes not so returned is equal to the minimum aggregate principal amount of such Designated Notes as is required to be surrendered in respect of the relevant number of Warrants being so exercised, it being specified that the portion (which may be the whole) of such excess which cannot be returned as a result of (i) and (ii) above will be forfeited by the Holder surrendering such Designated Notes and will not be refunded to such Holder. If there is more than one series of Designated Notes and more than one series of Designated Notes have been so surrendered, the series of Designated Notes for which any principal amount is returned pursuant to this clause (d) shall be determined by the Company in its sole discretion.
(e) Any accrued but unpaid interest on any Designated Notes surrendered to exercise Warrants (i) using the DWAC system shall be forfeited by the Holder surrendering such Designated Notes and (ii) using Electronic Exercise will be paid in cash as set forth on Exhibit B with respect to the principal amount of Designated Notes used to pay the DN Warrant Exercise Price (including the amount of any excess principal amount forfeited by the Holder surrendering such Designated Notes pursuant to Section 3.04(d)) and the amount of such cash shall be equal to the product of (x) a fraction, the numerator of which is such principal amount of Designated Notes and the denominator of which is $1,000 and (y) the Accrued Interest Amount in respect of the relevant Designated Notes (Electronic Exercise) Surrender Date, in each case except as set forth in the following sentence. If the Designated Notes (Electronic Exercise) Surrender Date in respect of a Designated Note falls after the regular record date in respect of any interest payment date and before such interest payment date with respect to such Designated Note (all as set forth in the indenture for such Designated Note), no forfeiture or payment will be made pursuant to the foregoing sentence and interest will be paid with respect to the principal balance of the Designated Note as of the record date in accordance with the applicable indenture. No additional accrued and unpaid interest will be paid on any Designated Notes surrendered pursuant to Section 3.04(a)(iii).
19
(f) Subject to Section 3.04(g), if the purported Exercise Request Date of any Warrants is or is deemed to be after the Close of Business on the Expiration Date, the exercise thereof will be null and void and any Funds or Designated Notes delivered to the Warrant Agent or the Company will be returned to the Holder as soon as practicable. In no event will interest accrue on Funds deposited with the Warrant Agent in respect of an exercise or attempted exercise of Warrants.
(g) Notwithstanding anything to the contrary herein, any otherwise valid exercise of a Warrant submitted after any applicable deadline for exercise may, in the sole and absolute discretion of the Company, be accepted and honored. The Company’s decision with respect to any such exercise shall be determinative.
(h) In the case of a Global Warrant, whenever some but not all of the Warrants represented by such Global Warrant are exercised in accordance with the terms thereof and of this Agreement, such Global Warrant shall be surrendered by the Holder to the Warrant Agent, which shall cause an adjustment to be made to such Global Warrant so that the number of Warrants represented thereby will be equal to the number of Warrants theretofore represented by such Global Warrant less the number of Warrants then exercised. The Warrant Agent shall thereafter promptly return such Global Warrant to the Holder or its nominee or custodian.
(i) In the case of a Definitive Warrant or book-entry Warrant, whenever some but not all of the Warrants represented by such Definitive Warrant or book-entry Warrant are exercised in accordance with the terms thereof and of this Agreement, the Holder shall be entitled, at the request of the Holder, to receive from the Company within a reasonable time, and in any event not exceeding ten (10) Business Days, a new Definitive Warrant or book-entry statement in substantially identical form for the number of Warrants equal to the number of Warrants theretofore represented by such Definitive Warrant or book-entry statement less the number of Warrants then exercised.
(j) If a Warrant Certificate shall have been exercised in full, the Warrant Agent shall promptly cancel such certificate following its receipt from the Holder or the Depositary, as applicable.
(k) If a Common Stock Shelf Registration Statement is not effective at any time or from time to time for any reason, the right to exercise Warrants shall be automatically suspended until such Common Stock Shelf Registration Statement becomes effective as specified in Section 5.01.
Section 3.05 Issuance of Warrant Shares.
(a) Subject to Section 3.02(a), upon any exercise of Warrants in compliance with this Agreement, the Company shall issue and cause the transfer agent for the Common Stock (the “Stock Transfer Agent,” which may be the Warrant Agent) to cause to be registered in the Company’s register of shareholders via the direct registration system a number of full Warrant Shares so purchased upon the exercise of such Warrants (determined in accordance with Section 3.06 or, if applicable, Section 3.08) or Units of Reference Property to which it is entitled, registered or otherwise, to the Holder or Holders entitled to receive the same or upon the written order of the Holder(s) in such name or names as the Holder(s) may designate (including any depositary institution so designated by a Holder); provided that no Warrant Shares shall be delivered to the Holder(s) before the occurrence of the relevant Exercise Date in respect of any exercise of Warrants, including the receipt of the Warrant Exercise Price in cash or by delivery of Designated Notes by the Company. In no event shall the Company have the right or obligation or be required to settle the exercise of Warrants through delivery of cash in lieu of Common Stock.
20
(b) Such Warrant Shares or Units of Reference Property shall be delivered after the applicable Exercise Date on the transfer agent’s standard turnaround time (and, in the case of any Electronic Exercise with Designated Notes, subject as set out in Exhibit B).
(c) The Company hereby instructs the Warrant Agent to record the cost basis for newly issued shares (or Units of Reference Property) as the sum of (x) the then applicable Warrant Exercise Price plus (y) the Holder’s cost basis in the exercised Warrant, if any, which the Warrant Agent shall request of the Holder, if necessary; provided that, in the case of an Automatic Net Exercise, the Company shall provide to the Warrant Agent in writing, together with the information transmitted pursuant to Section 3.08(c), the cost basis for the Warrant Shares (or Units of Reference Property) issued in respect of such Automatic Net Exercise, and the Warrant Agent shall record such cost basis as so provided by the Company and shall have no duty or obligation to calculate, investigate or confirm such cost basis.
(d) The Depositary’s (or the Calculation Agent’s) determination of the number of shares of Common Stock (or Units of Reference Property) to be issued on any exercise of Warrants and the validity of such exercise, pursuant to this Agreement, shall govern and the Warrant Agent shall have no duty or obligation to investigate or confirm whether such determinations are accurate or correct. If performed by the Calculation Agent, the determination of the number of shares of Common Stock (or Units of Reference Property) to be issued on any exercise of Warrants represented through the Company’s direct registration system or the Warrant Agent’s other book-entry procedures shall govern and the Warrant Agent shall have no duty or obligation to investigate or confirm whether such determination is accurate or correct.
(e) The Person in whose name any shares of Common Stock (or Units of Reference Property) shall be issuable upon exercise of a Warrant shall be treated as a stockholder of record of such shares (or holder of such Units of Reference Property) as of the Close of Business on the relevant Exercise Date, assuming the satisfaction of all conditions, including the payment of the Warrant Exercise Price. Upon the exercise of any Warrants, such Person shall no longer be a Holder of such Warrants as of the Close of Business on the relevant Exercise Date.
Section 3.06 Fractional Warrant Shares. The Company shall not be required to issue fractional shares of Common Stock (or Units of Reference Property) on the exercise of Warrants or pay cash in lieu thereof. The number of shares of Common Stock (or Units of Reference Property) that shall be issuable upon an exercise of Warrants by a Holder pursuant to any one Exercise Notice at any time shall be computed on the basis of the aggregate number of shares of Common Stock (or Units of Reference Property) which may be purchased pursuant to the Warrants being exercised by that Holder pursuant to such Exercise Notice. If any fraction of a share of Common Stock (or Units of Reference Property) would be issuable upon the exercise of Warrants pursuant to such Exercise Notice, the total number of shares of Common Stock (or Units of Reference Property) to be issued to the relevant Holder in respect of such Exercise Notice shall be rounded down to the nearest Whole Number (which may be equal to zero) and no cash or other adjustment will be made in lieu of the fraction of a share so rounded down.
21
Section 3.07 Reservation of Warrant Shares.
(a) The Company shall at all times keep reserved out of its authorized Common Stock a number of shares of Common Stock sufficient to provide for the exercise of all outstanding Warrants. The Company will keep a copy of this Agreement on file with the Stock Transfer Agent and will furnish to such Stock Transfer Agent a copy of all notices of adjustments (and certificates related thereto) transmitted to each Holder.
(b) The Company covenants that all Warrant Shares that may be issued upon proper exercise of the Warrants (including payment of the Warrant Exercise Price) shall, upon issue, be fully paid, nonassessable and free of preemptive rights.
(c) The Company shall provide an opinion of counsel on or prior to the date hereof which shall state that all Warrants and Warrant Shares, as applicable, (i) were offered, sold or issued as part of an offering that was registered in compliance with the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act (as the case may be), (ii) were issued in compliance with all applicable state securities or “blue sky” laws, and (iii) are validly issued, fully paid and non-assessable.
Section 3.08 Automatic Net Exercise.
(a) Warrants held by Holders who are directors and executive officers of the Company, as determined in the Company’s sole discretion (“Automatic Net Exercise Holders”) shall automatically, and without further action by an Automatic Net Exercise Holder, be exercised on the Expiration Date (which shall be the Exercise Date in respect of such exercise in accordance with the definition of such term) in accordance with this Section 3.08 (each such exercise, an “Automatic Net Exercise”). In exchange for the benefit of the Automatic Net Exercise provisions of this Section 3.08, Warrants held by Automatic Net Exercise Holders (i) may not be directly or indirectly transferred, sold or otherwise disposed of other than pursuant to a Permitted Transfer, and (ii) may only be exercised pursuant to this Section 3.08 on the Expiration Date, except as set forth in the final sentence of this Section 3.08(a). For purposes of this Section 3.08, “Permitted Transfer” means a transfer (w) to immediate family members (spouse, children, grandchildren, including by adoption) or a trust established solely for the benefit of such Automatic Net Exercise Holder and/or immediate family members, (x) to the Company, (y) by virtue of the laws of descent and distribution upon death of the Automatic Net Exercise Holder or (z) pursuant to a qualified domestic relations order, provided that in each case other than in the case of a transfer to the Company, such Warrants shall continue to be subject to this Section 3.08 and such transferee shall be an Automatic Net Exercise Holder. Notwithstanding the foregoing, Warrants may be exercised by Automatic Net Exercise Holders using Designated Notes (if there are Designated Notes as of the Exercise Request Date (but not using cash) in accordance with Section 3.04 prior to the earlier of (x) an Automatic Net Exercise and (y) the Expiration Date.
(b) Notwithstanding anything to the contrary in this Agreement, if any Warrant is automatically exercised pursuant to an Automatic Net Exercise pursuant to this Section 3.08, the Automatic Net Exercise Holder will not be required to pay the Warrant Exercise Price or deliver the Warrants or an Exercise Notice to exercise such Warrants and the number of Warrant Shares issuable for such exercise shall be calculated based on the following formula (subject to Section 3.08(d)):

Where:
| WS | = | the number of Warrant Shares issuable to the relevant Automatic Net Exercise Holder; and |
| NW | = | the number of Warrants held by the relevant Automatic Net Exercise Holder as of the Expiration Date; and |
| NES | = | the Automatic Net Exercise Shares per Warrant. |
22
“Automatic Net Exercise Shares per Warrant” means, per each Warrant subject to Automatic Net Exercise, the result (rounded to the nearest whole multiple of 0.00001 (with 0.000005 being rounded upwards) share of Common Stock) of the following formula:
VWAP(warrant)n
|
= | the Daily VWAP of a Warrant on the n-th Qualifying Trading Day (or, n-th S+W Trading Day, as the case may be) of the Automatic Net Exercise Calculation Period; | ||
| VWAP(share)n | = | the Daily VWAP of a share of Common Stock on the n-th Qualifying Trading Day (or, n-th S+W Trading Day, as the case may be) of the Automatic Net Exercise Calculation Period; and | ||
| N | = | the number of Qualifying Trading Days (if the Exercise Date is the Early Expiration Date) or S+W Trading Days (if the Exercise Date is the Scheduled Expiration Date) in the Automatic Net Exercise Calculation Period,
where “Automatic Net Exercise Calculation Period” means: | ||
| (1) | if the Exercise Date is the Early Expiration Date: the period comprising the 20 Qualifying Trading Days in the Reference Period; or | |||
| (2) | if the Exercise Date is the Scheduled Expiration Date: the 20 consecutive S+W Trading Days ending on (and including) the S+W Trading Day falling immediately preceding the Scheduled Expiration Date, | |||
| in each case subject to the final two paragraphs to this Section 3.08(b). | ||||
provided that, if on any Qualifying Trading Day (if the Exercise Date is the Early Expiration Date) or S+W Trading Day (if the Exercise Date is the Scheduled Expiration Date) that would (but for the operation of this paragraph) be included in the Automatic Net Exercise Calculation Period, the Daily Warrant VWAP Volume on such Qualifying Trading Day (or S+W Trading Day, as the case may be) is less than 0.1% of the number of Warrants outstanding on such Qualifying Trading Day (or S+W Trading Day, as the case may be), such Qualifying Trading Day (or S+W Trading Day, as the case may be) will not be included in the Automatic Net Exercise Calculation Period, and the Automatic Net Exercise Calculation Period will include only Qualifying Trading Days (or S+W Trading Days, as the case may be) for which the Daily Warrant VWAP Volume is at least 0.1% of the number of Warrants outstanding on such Qualifying Trading Day (or S+W Trading Day, as the case may be) (each such Qualifying Trading Day (or S+W Trading Day, as the case may be) on which such condition is met, an “Eligible Trading Day”),
23
provided further that if, as a result of the operation of the immediately preceding paragraph, there would (but for the operation of this further paragraph) be fewer than 15 Eligible Trading Days, then the Automatic Net Exercise Calculation Period shall instead comprise the 15 Qualifying Trading Days (or S+W Trading Days, as the case may be) amongst such 20 Qualifying Trading Days (or amongst such 20 consecutive S+W Trading Days, as the case may be) with the highest Daily Warrant VWAP Volumes.
(c) On the Expiration Date, the Company (or, as may be agreed between the Calculation Agent and the Company, the Calculation Agent) shall promptly calculate and transmit to the Warrant Agent in writing, the number of whole Warrants to debit and the number of whole Warrant Shares issuable in connection with each such Automatic Net Exercise. The Warrant Agent shall have no obligation under this Agreement to calculate, the number of Warrant Shares issuable in connection with such Automatic Net Exercise, nor shall the Warrant Agent have any duty or obligation to investigate or confirm whether the Company’s determination of the number of Warrant Shares issuable upon such exercise, pursuant to this Section 3.08, is accurate or correct.
(d) If VWAP(share)n (as defined in the definition of “Automatic Net Exercise Shares per Warrant”) is equal to zero on any Qualifying Trading Day (or S+W Trading Day, as the case may be) in the Automatic Net Exercise Calculation Period, then the number of Warrant Shares issuable for all Automatic Net Exercises shall be zero and the Warrants so exercised shall cease to be outstanding. For the avoidance of doubt, the number of Warrant Shares issuable pursuant to this Section 3.08 shall be subject to Section 3.06 (in particular, if WS (as defined in Section 3.08(b)) is less than one (1) in respect of any Automatic Net Exercise, then the number of Warrant Shares issuable in respect of such Automatic Net Exercise shall be zero and the Warrants so exercised shall cease to be outstanding).
Section 3.09 Adjustments of Prices. Whenever any provision of this Agreement requires the Company or the Calculation Agent to calculate the average of the daily Last Reported Sale Prices or Daily VWAPs of a share of Common Stock over a span of multiple days (if the Calculation Agent determines in its sole discretion it is able to make such adjustment in its capacity as Calculation Agent), the Company or the Calculation Agent, as applicable, shall make appropriate adjustments, if any, to each such price to account for any adjustment pursuant to Section 4.01 to the Warrant Exercise Rate that becomes effective, or any event requiring an adjustment pursuant to Section 4.01 to the Warrant Exercise Rate where the Ex-Date or effective date, as the case may be, of the event occurs, at any time during or after the period when the average of such Last Reported Sale Prices or Daily VWAPs is to be calculated. If the Calculation Agent determines in its sole discretion it is not able to make such adjustment, the Company may make such adjustment in good faith or appoint an Independent Advisor to make such adjustment, and the Company’s (or, as the case may be, such Independent Advisor’s) calculation shall be determinative and final and binding on the Warrant Agent, the Calculation Agent and the Holders.
24
Article IV
Adjustment and Notice Provisions
Section 4.01 Adjustments.
Subject to the provisions of this Article IV, the Warrant Exercise Rate shall be subject to adjustment, without duplication, as follows, except that the Company shall not make any such adjustments if the Company determines that each Holder has the opportunity to participate, at the same time and upon the same terms as holders of the shares of Common Stock and solely as a result of holding the Warrants in any of the transactions described in this Section 4.01, without having to exercise such Holder’s Warrants, as if such Holder held a number of shares of Common Stock equal to the product (rounded down to the nearest Whole Number) of (i) the Warrant Exercise Rate in effect on the Record Date for such transaction and (ii) the number of Warrants held by it on such Record Date:
(a) Stock Dividends, Splits, Subdivisions, Reclassifications and Combinations. If the Company shall (i) exclusively issue shares of Common Stock to all or substantially all holders of Common Stock as a dividend or distribution on shares of the Common Stock, (ii) subdivide or reclassify the issued and outstanding shares of Common Stock into a greater number of shares, or (iii) combine, consolidate or reclassify the issued and outstanding shares of Common Stock into a smaller number of shares, then the Warrant Exercise Rate shall be adjusted based on the following formula:
where:
| WER1 | = | the Warrant Exercise Rate in effect at the open of business on the Ex-Date for such dividend or distribution, or at the open of business on the effective date of such subdivision, combination, consolidation or reclassification, as applicable; |
| WER0 | = | the Warrant Exercise Rate in effect immediately prior to the open of business on the Ex-Date for such dividend or distribution, or immediately prior to open of business on the effective date of such subdivision, combination, consolidation or reclassification, as applicable; |
| OS1 | = | the number of shares of Common Stock outstanding immediately after, and solely as a result of giving effect to, such dividend, distribution, subdivision, combination, consolidation or reclassification, as applicable; |
| OS0 | = | the number of shares of Common Stock outstanding immediately prior to the open of business on the Ex-Date for such dividend or distribution or immediately prior to the open of business on the effective date of such subdivision, combination, consolidation or reclassification, as applicable (before giving effect to any such dividend, distribution, or subdivision, consolidation, combination or reclassification, as applicable). |
25
Any adjustment made under this clause (a) shall become effective at the open of business on such Ex-Date for such dividend or distribution, or at the open of business on the effective date for such subdivision, consolidation, combination or reclassification, as applicable. If an adjustment to the Warrant Exercise Rate is made in respect of any dividend or distribution, subdivision, consolidation, combination or reclassification of the type described in this clause (a) but such dividend or distribution, subdivision, consolidation, combination or reclassification is not so paid or made, the Warrant Exercise Rate shall be readjusted, effective as of the date the Board of Directors determines not to pay or make such dividend or distribution, subdivision, consolidation, combination or reclassification, to the Warrant Exercise Rate that would then be in effect at such time had no such adjustment been made.
(b) Rights Issues. If the Company issues to all or substantially all holders of the Common Stock any rights, options or warrants entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than the arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the period of 10 consecutive Trading Days immediately preceding the date of announcement of such issuance, the Warrant Exercise Rate shall be increased based on the following formula:
where:
| WER1 | = | the Warrant Exercise Rate in effect at the open of business on the Ex-Date for such issuance; |
| WER0 | = | the Warrant Exercise Rate in effect immediately prior to the open of business on the Ex-Date for such issuance; |
| OS0 | = | the number of shares of Common Stock outstanding immediately prior to the open of business on the Ex-Date for such issuance; |
| X | = | the total number of shares of Common Stock issuable pursuant to such rights, options or warrants; and |
| Y | = | the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the period of 10 consecutive Trading Days immediately preceding the date of announcement of the issuance of such rights, options or warrants. |
Any adjustment to the Warrant Exercise Rate made under this clause (b) shall be made whenever any such rights, options or warrants are issued and shall become effective at the open of business on the Ex-Date for such issuance. To the extent that shares of the Common Stock are not delivered after the expiration of such rights, options or warrants, the Warrant Exercise Rate shall be decreased to the Warrant Exercise Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered. If an adjustment to the Warrant Exercise Rate is made in respect of any such issuance of rights, options or warrants but such rights, options or warrants are not so issued, the Warrant Exercise Rate shall be readjusted, effective as of the date the Board of Directors determines not to issue such rights, options or warrants, to the Warrant Exercise Rate that would then be in effect at such time had no such adjustment been made.
For purposes of this clause (b), in determining whether any rights, options or warrants entitle the holders of the Common Stock to subscribe for or purchase shares of the Common Stock at less than such arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the period of 10 consecutive Trading Days immediately preceding the date of announcement for such issuance, and in determining the aggregate offering price of such shares of Common Stock, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the Board of Directors.
26
(c) Other Distributions and Spin-Offs.
(i) Distributions Other than Spin-Offs. If the Company makes a distribution to all or substantially all holders of its Common Stock, of its Capital Stock, evidences of indebtedness, other assets or property of the Company, or rights, options or warrants to acquire its Capital Stock or other securities, excluding:
(1) any dividends, distributions or issuances described in clause (a) above or clause (b) above, or any other dividends, distributions or issuances by the Company of any rights, options or warrants to purchase shares of Common Stock (including without limitation any additional Warrants issued pursuant to Section 2.01(a)(iv));
(2) any dividends or distributions paid exclusively in cash described in clause (d) below;
(3) any dividends or distributions in connection with a Business Combination, reclassification, change, consolidation conveyance, transfer, sale, lease or other disposition resulting in the change in the securities or property receivable upon the exercise of a warrant as described in Section 4.03;
(4) any rights issued pursuant to a shareholders’ rights plan adopted by the Company as described in clause (e) below; and
(5) any Spin-Offs described below in Section 4.01(c)(ii),
then the Warrant Exercise Rate shall be increased based on the following formula:
where:
| WER1 | = | the Warrant Exercise Rate in effect at the open of business on the Ex-Date for such distribution; |
| WER0 | = | the Warrant Exercise Rate in effect immediately prior to the open of business on the Ex-Date for such distribution; |
| SP0 | = | the arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the period of 10 consecutive Trading Days immediately preceding the Ex-Date for such distribution; and |
| FMV | = | the Fair Market Value, as of the open of business on the Ex-Date for such distribution, of the shares of Capital Stock, evidences of indebtedness, assets or property of the Company, cash, rights or warrants distributed with respect to each outstanding share of Common Stock. |
27
Any adjustment to the Warrant Exercise Rate under this clause (c)(i) shall become effective at the open of business on the Ex-Date for such distribution.
(ii) Spin-Offs. With respect to an adjustment pursuant to this clause (c) where there has been a payment of a dividend or other distribution by the Company to all or substantially all holders of its Common Stock in shares of Capital Stock of any class or series, or similar equity interests, of or relating to a subsidiary or other business unit of the Company that will be, upon distribution, listed or quoted on a U.S. national or regional securities exchange (a “Spin-Off”), then the Warrant Exercise Rate shall be increased based on the following formula:
where:
| WER1 | = | the Warrant Exercise Rate in effect at the open of business on the Ex-Date of the Spin-Off; |
| WER0 | = | the Warrant Exercise Rate in effect immediately prior to the open of business on the Ex-Date of the Spin-Off; |
| FMV | = | the arithmetic average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common Stock applicable to one share of Common Stock on each day which is a Trading Day for both the Common Stock and the Capital Stock or similar equity interest so distributed (each, a “Valuation Trading Day”) comprised in the period of 10 consecutive Valuation Trading Days commencing on the Ex-Date for such Spin-Off (or, if such Ex-Date is not a Valuation Trading Day, commencing on the immediately following Valuation Trading Day) (such period, the “Valuation Period”); and |
| SP0 | = | the arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the Valuation Period. |
Any adjustment to the Warrant Exercise Rate under this clause (c)(ii) shall be made immediately after the Close of Business on the last day of the Valuation Period, but shall become effective at the open of business on the Ex-Date for the Spin-Off, subject to Section 4.02(b).
If an adjustment to the Warrant Exercise Rate is made in respect of any distribution of the type described in this clause (c) but such distribution is not so made, the Warrant Exercise Rate shall be readjusted, effective as of the date the Board of Directors determines not to make such distribution, to the Warrant Exercise Rate that would then be in effect at such time had no such adjustment been made.
28
(d) Cash Dividends or Distributions. If any cash dividend or distribution is paid to all or substantially all holders of Common Stock, then the Warrant Exercise Rate shall be increased based on the following formula:
where:
| WER1 | = | the Warrant Exercise Rate in effect at the open of business on the Ex-Date for such dividend or distribution; and |
| WER0 | = | the Warrant Exercise Rate in effect immediately prior to the open of business on the Ex-Date for such dividend or distribution; |
| SP0 | = | the arithmetic average of the Last Reported Sale Prices of the Common Stock on each Trading Day comprised in the period of 10 consecutive Trading Days immediately preceding the Ex-Date for such dividend or distribution; and |
| C | = | the amount in cash per share the Company distributes to holders of the Common Stock; |
Any adjustment to the Warrant Exercise Rate made under this clause (d) shall become effective at the open of business on the Ex-Date for such dividend or distribution. If an adjustment to the Warrant Exercise Rate is made in respect of any dividend or distribution of the type described in this clause (d) but such dividend or distribution is not so paid, the Warrant Exercise Rate shall be readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution, to the Warrant Exercise Rate that would then be in effect at such time had no such adjustment been made.
(e) Shareholder Rights Plan. If the Company has a shareholder rights plan in effect upon the Exercise Date of a Warrant, each share of Common Stock, if any, issued upon such exercise shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Common Stock issued upon such exercise shall bear such legends, if any, in each case as may be provided by the terms of any such shareholder rights plan, as the same may be amended from time to time. However, if, prior to any exercise, the rights have separated from the shares of Common Stock in accordance with the provisions of the applicable shareholder rights plan so that the Holders of Warrants would not be entitled to receive any rights in respect of Common Stock, if any, issuable upon exercise, the Warrant Exercise Rate shall be adjusted at the time of separation as if the Company had made a distribution to all holders of its Common Stock as provided in Section 4.01(b), subject to readjustment in the event of the expiration, termination or redemption of such rights.
29
(f) No Adjustments in Certain Cases. The Company will not be required to adjust the Warrant Exercise Rate except as provided in this Section 4.01. Without limiting the foregoing, the Company will not be obligated to adjust the Warrant Exercise Rate on account of:
(1) except as otherwise provided in Section 4.01, the sale of shares of Common Stock, or rights, options or warrants to purchase shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, or the right to purchase such rights, options or warrants or convertible or exchangeable securities;
(2) the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any such plan;
(3) the issuance of any shares of Common Stock or options or rights to purchase shares of Common Stock pursuant to any present or future employee, director or consultant benefit plan or program of, or assumed by, the Company or any of its subsidiaries;
(4) the issuance of any shares of Common Stock pursuant to any option, warrant, right or convertible or exchangeable security of the Company outstanding as of the Issue Date; or
(5) solely a change in the par value of the Common Stock.
Section 4.02 Calculation of Adjustments; Timing of Issuance of Additional Warrant Shares Upon Certain Adjustments; Adjustment Rules.
(a) All adjustments to the Warrant Exercise Rate under Section 4.01 shall be made by the Calculation Agent to the nearest whole multiple of 0.00001 (with 0.000005 being rounded upwards) share of Common Stock.
(b) Notwithstanding anything to the contrary in this Agreement or the Warrants, (i) if the provisions of Section 4.01 shall require that an adjustment be made to the Warrant Exercise Rate in respect of any distribution or other relevant event, and the shares of Common Stock issuable in respect of any exercise are entitled to participate in such distribution or other relevant event, such adjustment shall not be given effect for the purpose of such exercise of Warrants and (ii) if the Exercise Date in respect of any exercise of Warrants falls after the Record Date for any Spin-Off and on or before the last day of the relevant Valuation Period, delivery of the shares of Common Stock issuable pursuant to such exercise shall occur as soon as practicable after the last day of such Valuation Period.
(c) Any adjustments pursuant to Section 4.01 shall be made successively whenever an event referred to therein shall occur.
30
(d) The DN Warrant Exercise Price shall be subject to adjustment upon any amendment of the Warrant Exercise Price in accordance with Section 4.06 to be equal to $1,000 in principal amount of Designated Notes to exercise up to (or, in the case of an Electronic Exercise, to exercise not more and not less than) such number of Warrants as is equal to $1,000 divided by the Warrant Exercise Price so amended (rounded to the nearest Whole Number of Warrants). The Company hereby agrees that it will provide the Warrant Agent with reasonable notice of any adjustment event. The Company further agrees that it will provide the Warrant Agent with any new or amended exercise terms. The Warrant Agent shall have no obligation under any Section of this Agreement to determine whether an adjustment event has occurred or to calculate any of the adjustments set forth herein.
Section 4.03 Business Combinations and Reorganizations. In case of any Business Combination or reclassification of Common Stock (other than a reclassification of Common Stock referred to in Section 4.01), the Holder’s right to receive Warrant Shares upon exercise of a Warrant shall be converted into the right to exercise a Warrant to acquire, per each Warrant, the number of shares or other securities or property (including cash) that a number of shares of Common Stock equal to the Warrant Exercise Rate (in effect at the time of such Business Combination or reclassification) immediately prior to such Business Combination or reclassification would have been entitled to receive upon consummation of such Business Combination or reclassification (the amount of such shares, other securities or property in respect of a share of Common Stock being herein referred to as a “Unit of Reference Property”); and in any such case, if necessary, the provisions set forth herein with respect to the rights and interests thereafter of the Holder shall be appropriately adjusted so as to be applicable, as nearly as may reasonably be achievable, to the Holder’s right to exercise such Warrant in exchange for a Unit of Reference Property pursuant to this paragraph. If the Business Combination causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election), then the composition of the Unit of Reference Property into which the Warrants will be exercisable shall be deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Common Stock.
Section 4.04 Notice of Adjustments. Whenever any adjustment is made pursuant to this Article IV, the Company shall cause notice of such adjustment to be delivered to the Warrant Agent as soon as practicable following the effective date of such adjustment, such notice to include in reasonable detail (i) the reason for the adjustment, (ii) the computation of any adjustments, and (iii) the new or amended exercise terms, including, as applicable, the adjusted Warrant Exercise Rate (or the number of shares or the Units of Reference Property purchasable upon exercise of each Warrant) and the Early Expiration Trigger Price after giving effect to such adjustment. The calculations, adjustments and determinations included in the Company’s notice shall, absent manifest error, be final and binding on the Company, the Warrant Agent and the Holders. The Warrant Agent shall be entitled to rely on such notice and any adjustment therein contained and the Warrant Agent shall not be deemed to have knowledge of any such adjustment unless and until it shall have received such notice. The Warrant Agent shall have no obligation under any section of this Agreement to determine whether an adjustment is required or to calculate any of the adjustments set forth herein. The Company shall provide notice to the holders of Warrants of any such adjustment by press release or such other method as the Company may reasonably determine adequately informs holders of Warrants of such adjustment. The Warrant Agent shall as soon as practicable after receipt of such notice from the Company (which notice must specifically direct the Warrant Agent to perform delivery) cause a similar notice to be delivered to the Depositary pursuant to the customary procedures of the Depositary.
31
Section 4.05 Adjustment to Warrant Certificate. The form of Warrant Certificate need not be changed because of any adjustment made pursuant to this Article IV, and Warrant Certificates issued after such adjustment may state the same Warrant Exercise Rate as are stated in any Warrant Certificates issued prior to such adjustment. The Company, however, may at any time in its sole discretion make any change in the form of any Warrant Certificate that it may deem appropriate to give effect to such adjustments and that does not affect the substance of the Warrant Certificate, and any Warrant Certificate thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant Certificate or otherwise, may be in the form as so changed. For the avoidance of doubt, no change to the Warrant Certificate or this Agreement as a result of an adjustment pursuant to this Article IV shall require the consent of the Holders of the Warrants or the Warrant Agent.
Section 4.06 Amendments.
(a) The Company and the Warrant Agent, without the consent of the Holders, may from time to time and at any time amend this Agreement and/or any Warrant Certificate for one or more of the following purposes:
(i) to cure any ambiguity, omission, defect or inconsistency;
(ii) to provide for the assumption by a successor company in any Business Combination;
(iii) to extend the Scheduled Expiration Date;
(iv) to increase the Warrant Exercise Rate for a period specified in the applicable amendment;
(v) to decrease the Warrant Exercise Price for a period specified in the applicable amendment;
(vi) to provide for net share settlement upon exercise of any Warrants in a manner other than as provided in Section 3.08 or amend the terms of Section 3.08;
(vii) to make any change that does not adversely affect the rights of any Holder in any material respect, including with respect to the manner of exercise of the Warrants (including as set out in Exhibit B to this Agreement);
(viii) to provide for a successor Warrant Agent or Calculation Agent;
(ix) in connection with any Business Combination, to provide that Warrants are exercisable for Units of Reference Property;
(x) to comply with the rules of any applicable Depositary so long as such amendment does not adversely affect the rights of any Holder in any material respect;
(xi) to conform the provisions of this Agreement or the Warrant Certificate to the “Description of the Warrants” section of the prospectus supplement relating to the issuance and sale of shares of Common Stock upon exercise of the Warrants; or
(xii) to provide for or confirm the issuance of additional Warrants pursuant to Section 2.01(a)(iv).
32
Any amendment authorized by the provisions of this Section 4.06(a) may be executed by the Company and the Warrant Agent without the consent of the Holders of any of the Warrants at the time outstanding, notwithstanding any of the provisions of Section 4.06(b). The Warrant Agent shall not unreasonably refuse to execute any such amendment proposed by the Company.
(b) With the written consent of the Holders of a majority of the then outstanding Warrants, the Company may from time to time amend this Agreement and/or the Warrant Certificate in a manner that has a material adverse effect on the interests of the Holders. In determining whether the Holders of the required number of Warrants have concurred in any direction, waiver or consent, only Warrants outstanding at the time shall be considered in any such determination, and the Warrants known to the Warrant Agent to be owned by the Company shall be disregarded and deemed not to be outstanding for such purpose. The Company or the Warrant Agent may set a record date for any such direction, waiver or consent and only the Holders as of such record date shall be entitled to make or give such direction, waiver or consent.
(c) No supplement or amendment to this Agreement or any Warrant Certificate shall be effective unless duly executed by the Warrant Agent and the Company. As a condition precedent to the Warrant Agent’s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized Officer of the Company that states that the proposed amendment is in compliance with the terms of Section 4.06. Notwithstanding anything in this Agreement to the contrary, the Warrant Agent may, but shall not be obligated to, enter into any supplement or amendment that adversely affects the Warrant Agent’s own rights, duties, immunities or obligations under this Agreement.
(d) The Company shall provide reasonable notice to the Holders via press release or Form 8-K filing of any material amendment to this Agreement or the Warrant Certificate pursuant to this Section 4.06, and in each case materiality shall be determined by the Company in its reasonable discretion. The Warrant Agent shall as soon as practicable after receipt of such notice from the Company (which notice must specifically direct the Warrant Agent to perform delivery) cause a similar notice to be delivered to the Depositary pursuant to the customary procedures of the Depositary. Upon the execution of any amendment of this Agreement or the Warrant Certificate pursuant to the provisions of this Section 4.06, this Agreement and/or the Warrant Certificate shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Agreement of the Company, the Warrant Agent and the Holders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such amendment shall be and be deemed to be part of the terms and conditions of this Agreement and the Warrant Certificate for any and all purposes.
33
Article V
Registration of Warrant Shares
Section 5.01 Effectiveness of Registration Statement. The Company shall use commercially reasonable efforts to cause a shelf registration statement (including, at the Company’s election, an existing registration statement or a replacement thereof), filed pursuant to Rule 415 (or any successor provision) of the Securities Act, covering the issuance of Warrant Shares to the Holders upon exercise of the Warrants by the Holders thereof (the “Common Stock Shelf Registration Statement”) to, subject to certain exceptions, (i) become effective as promptly as reasonably practicable after the date of this Agreement and (ii) remain effective at least until the earlier of (x) such time as all Warrants have been exercised and (y) the Close of Business on the Expiration Date. The Company shall promptly inform the Warrant Agent of any change in the status of the effectiveness or availability of the Common Stock Shelf Registration Statement. For the avoidance of doubt, no Warrants shall be exercisable at any time until a Common Stock Shelf Registration Statement becomes effective. If a Common Stock Shelf Registration Statement is not effective at any time or from time to time for any reason, the right to exercise Warrants shall be automatically suspended until such Common Stock Shelf Registration Statement becomes effective (any such period, an “Exercise Suspension Period”). As promptly as practicable upon the occurrence of an Exercise Suspension Period, the Company shall provide notice by press release, with a copy to the Warrant Agent and the Calculation Agent, of any Exercise Suspension Period. Notwithstanding anything to the contrary in this Agreement, (i) no observation of the Daily VWAP of a share of Common Stock for purposes of determining the Early Expiration Price Condition shall occur during any Exercise Suspension Period, and (ii) if the Expiration Date would otherwise fall in an Exercise Suspension Period, the Expiration Date shall be delayed by the number of days comprised in such Exercise Suspension Period.
Section 5.02 Suspension. The Company shall be entitled to suspend the availability of the Common Stock Shelf Registration Statement from time to time if the Board of Directors determines in the exercise of its reasonable judgment that such suspension is necessary or desirable, as determined by the Company in its sole discretion, and provides notice via press release that such determination was made to the Warrant Agent and Holders of the Warrants (provided that, upon request by the Company, the Stock Transfer Agent will deliver a copy of such notice to the Depositary pursuant to the customary procedures of the Depositary) provided, however, that (i) if the Company exercises such right in a period in which the Expiration Date would otherwise fall, the Expiration Date shall be delayed by the number of days during such period for which the availability of the Common Stock Shelf Registration Statement was suspended and no observation of the Daily VWAP of a share of Common Stock for purposes of determining the Early Expiration Price Condition will occur in any such period and (ii) in no event shall the Company be required to disclose the business purpose for such suspension if the Company determines in good faith that such business purpose should remain confidential.
Section 5.03 Expenses. Subject to Section 2.04(c)(ii), all expenses incurred directly by the Company that are incidental to the Company’s performance of or compliance with its obligations under this Article V relating to the issuance of the Warrant Shares will be borne by the Company, including, without limitation: (i) all SEC, stock exchange or Financial Industry Regulatory Authority registration and filing fees, (ii) all fees and expenses incurred by the Company in connection with the compliance with state securities or blue sky laws, (iii) all expenses of any Persons incurred by or on behalf of the Company with the prior written consent of the Company in preparing or assisting in preparing, printing and distributing the Common Stock Shelf Registration Statement or any other registration statement, prospectus, any amendments or supplements thereto and other documents relating to the performance of and compliance with this Article V, (iv) the fees and disbursements of counsel for the Company and (v) the fees and disbursements of the independent public accountants of the Company.
34
Article VI
Warrant Agent
Section 6.01 Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the express provisions of this Agreement and the Warrant Agent hereby accepts such appointment.
Section 6.02 Rights and Duties of Warrant Agent.
(a) Agent for the Company. In acting under this Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligation or relationship of agency or trust for or with any of the holders of Warrant Certificates or beneficial owners of Warrants. All fees and expenses due the Warrant Agent shall be paid to the Warrant Agent by the Company. The Warrant Agent shall have no duty to determine which costs, if any, under this Agreement shall be borne by the Holders or by the Company.
(b) Counsel. The Warrant Agent may consult with counsel satisfactory to it (who may be counsel to the Company) and the advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in the absence of bad faith (which bad faith must be determined by a final non-appealable order, judgment, decree or ruling of a court of competent jurisdiction) and in accordance with the advice of such counsel.
(c) Documents. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper parties.
(d) No Implied Obligations. The Warrant Agent shall be obligated to perform only such duties as are specifically set forth herein and in the Warrant Certificates, and no implied duties or obligations of the Warrant Agent shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder that may tend to involve it in any expense or liability for which it does not receive indemnity if such indemnity is reasonably requested. The Warrant Agent shall not be accountable or under any duty or responsibility for the application by the Company of the proceeds of the Warrants. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a Holder with respect to such default, including any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise.
35
(e) Not Responsible for Adjustments or Validity of Stock. The Warrant Agent shall not at any time be under any duty or responsibility to any Holder to determine whether any facts exist that may require an adjustment of the Warrant Exercise Rate, or with respect to the nature or extent of any adjustment when made, or with respect to the method employed, or herein or in any supplemental agreement provided to be employed, in making the same, or with respect to any new exercise terms, or with respect to calculations of any adjustments or any amounts due in connection with any exercise of the Warrants. The Warrant Agent shall not be accountable with respect to the validity or value of any shares of Common Stock or of any securities or property which may at any time be issued or delivered upon the exercise of any Warrant or upon any adjustment pursuant to Article IV, and the Warrant Agent makes no representation with respect thereto. The Warrant Agent shall not be responsible for any failure of the Company to make any cash payment or to issue, transfer or deliver any Warrant Shares upon the surrender of any Warrant Certificate for the purpose of exercise, nor shall the Warrant Agent be liable for any liquidated damages or any other damages associated therewith.
(f) No Liability for Interest. The Warrant Agent shall have no liability for interest on any monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.
(g) Agents and Attorneys. The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or subcontractors or for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final, non-appealable judgment of a court of competent jurisdiction) in the selection or continued employment thereof.
(h) Medallion Guarantee. The Warrant Agent may rely on and be fully authorized and protected in acting or failing to act upon (i) any guaranty of signature by an “eligible guarantor institution” that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable “signature guarantee program” or insurance program in addition to, or in substitution for, the foregoing; or (ii) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.
Section 6.03 Individual Rights of Warrant Agent. The Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or its Affiliates or become pecuniary interested in transactions in which the Company or its Affiliates may be interested, or contract with or lend money to the Company or its Affiliates or otherwise act as fully and freely as though it were not the Warrant Agent under this Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity.
36
Section 6.04 Warrant Agent’s Disclaimer. The Warrant Agent shall not be responsible for and makes no representation as to the validity or adequacy of this Agreement or the Warrant Certificates (other than its countersignature thereof) and it shall not be responsible for any statements of fact or recitals contained in this Agreement or the Warrant Certificates other than its countersignature thereof, or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only; nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant Certificate; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued, be duly authorized, validly issued, fully paid and nonassessable.
Section 6.05 Compensation and Indemnity.
(a) Compensation. The Company agrees that the Warrant Agent is entitled, from time to time, to reasonable compensation for its services as agreed in accordance with a fee schedule to be mutually agreed upon between the Company and the Warrant Agent in writing for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable out-of-pocket expenses (including reasonable and documented counsel fees and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder) by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent.
(b) Indemnity. The Company covenants and agrees to indemnify and to hold the Warrant Agent harmless against any loss, liability, damage, judgment, fine, penalty, claim, demand, settlement, cost or expense (including the reasonable fees and expenses of legal counsel) (collectively, “Losses”) which may be paid, incurred or suffered by or to which it may become subject arising from or out of, directly or indirectly, any claims or liability resulting from any action taken, suffered or omitted by the Warrant Agent in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the reasonable costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or of enforcing its rights under this Agreement; provided that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect to such Losses . y incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence, bad faith or willful misconduct (which gross negligence, bad faith or willful misconduct must be determined by a final, non-appealable judgment of a court of competent jurisdiction).
(c) Company Instructions. From time to time, the Company may provide the Warrant Agent with instructions concerning the services performed by the Warrant Agent hereunder. In addition, at any time the Warrant Agent may apply to any officer of the Company for instruction, and may consult with legal counsel for the Warrant Agent or the Company with respect to any matter arising in connection with the services to be performed by the Warrant Agent under this Agreement. The Warrant Agent and its agents and subcontractors shall not be liable and shall be indemnified by the Company for any action taken or omitted by the Warrant Agent in reliance upon any Company instructions or upon the advice or opinion of such counsel. The Warrant Agent shall not be held to have notice of any change of authority of any person, until receipt of written notice thereof from the Company.
37
(d) Limitation of Liability. The Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct (each as determined by a final, non-appealable judgment of a court of competent jurisdiction). Notwithstanding anything contained herein to the contrary, the Warrant Agent’s aggregate liability during any term of this Agreement with respect to, arising from, or arising in connection with this Agreement, or from all services provided or omitted to be provided under this Agreement, whether in contract, or in tort, or otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Company to the Warrant Agent as fees and charges, but not including reimbursable expenses, during the twelve (12) months immediately preceding the event for which recovery from Warrant Agent is being sought.
(e) Consequential Damages. Neither party to this Agreement shall be liable to the other party for any consequential, indirect, special or incidental damages under any provisions of this Agreement or for any consequential, indirect, punitive, special or incidental damages arising out of any act or failure to act hereunder even if that party has been advised of or has foreseen the possibility of such damages.
(f) Survival. The Parties’ obligations pursuant to this Section 6.05 shall survive the termination, exercise or expiration of the Warrants, the termination of this Agreement and the resignation, replacement or removal of the Warrant Agent.
Section 6.06 Successor Warrant Agent.
(a) Company to Provide and Maintain Warrant Agent. The Company agrees for the benefit of the Holders that there shall at all times be a Warrant Agent hereunder (which may include the Company) until all the Warrants have been exercised or are no longer exercisable.
(b) Resignation and Removal. The Warrant Agent may at any time resign by giving written notice to the Company of such intention on its part, specifying the date on which its desired resignation shall become effective; provided, however, that such date shall not be less than thirty (30) days after the date on which such notice is given unless the Company otherwise agrees in writing. In the event the transfer agency relationship in effect between the Company and the Warrant Agent terminates, the Warrant Agent will be deemed to have resigned automatically, subject to the second clause of the preceding sentence, and will be discharged from its duties under this Agreement as of the effective date of such termination, and the Company shall be responsible for sending any required notice. The Warrant Agent hereunder may be removed at any time by the filing with it of an instrument in writing signed by or on behalf of the Company and specifying such removal and the date when it shall become effective, which date shall not be fewer than thirty (30) days after such notice is given unless the Warrant Agent otherwise agrees in writing.
(c) The Company to Appoint Successor. In the event that at any time the Warrant Agent shall resign, or shall be removed, or shall become incapable of acting, or shall be adjudged bankrupt or insolvent, or shall commence a voluntary case under the federal bankruptcy laws, as now or hereafter constituted, or under any other applicable federal or state bankruptcy, insolvency or similar law or shall consent to the appointment of or taking possession by a receiver, custodian, liquidator, assignee, trustee, sequestrator (or other similar official) of the Warrant Agent or its property or affairs, or shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts generally as they become due, or shall take corporate action in furtherance of any such action, or a decree or order for relief by a court shall have been entered in respect of the Warrant Agent in an involuntary case under the federal bankruptcy laws, as now or hereafter constituted, or any other applicable federal or state bankruptcy, insolvency or similar law, or a decree or order by a court shall have been entered for the appointment of a receiver, custodian, liquidator, assignee, trustee, sequestrator (or similar official) of the Warrant Agent or of its property or affairs, or any public officer shall take charge or control of the Warrant Agent or of its property or affairs for the purpose of rehabilitation, conservation, winding up or liquidation, a successor Warrant Agent, qualified as aforesaid, shall be appointed by the Company by an instrument in writing, filed with the successor Warrant Agent. Notwithstanding the foregoing, if the Company fails to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent, then the incumbent Warrant Agent may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent. Pending appointment of a successor to such Warrant Agent either by the Company or by such court, the duties of the Warrant Agent shall be carried out by the Company.
38
(d) Successor to Expressly Assume Duties. Any successor Warrant Agent appointed hereunder shall execute, acknowledge and deliver to its predecessor and to the Company an instrument accepting such appointment hereunder, and thereupon such successor Warrant Agent, without any further act, deed or conveyance, shall become vested with all the rights and obligations of such predecessor with like effect as if originally named as Warrant Agent hereunder, and such predecessor, upon payment of its charges and disbursements then unpaid, shall thereupon become obligated to transfer, deliver and pay over, and such successor Warrant Agent shall be entitled to receive, all monies, securities and other property on deposit with or held by such predecessor, as Warrant Agent hereunder; provided that, the predecessor Warrant Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing.
(e) Successor by Merger. Any Person into which the Warrant Agent hereunder may be merged or consolidated, or any Person resulting from any merger or consolidation to which the Warrant Agent shall be a party, or any Person to which the Warrant Agent shall sell or otherwise transfer all or substantially all of its assets and business, shall be the successor Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the Parties.
Section 6.07 Bank Accounts. All funds administered by Computershare under this Agreement that are to be distributed or applied by Computershare in the performance of services (the “Funds”) shall be administered by Computershare as agent for the Company and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for the Company. Until paid pursuant to this Agreement, Computershare may administer or invest the Funds through such accounts in: (a) funds backed by obligations of, or guaranteed by, the United States of America; (b) debt or commercial paper obligations rated A-1 or P-1 or better by S&P Global Inc. (“S&P”) or Moody’s Investors Service, Inc. (“Moody’s”), respectively; (c) Government and Treasury backed AAA-rated Fixed NAV money market funds that comply with Rule 2a-7 of the Investment Company Act of 1940, as amended; or (d) short term certificates of deposit, bank repurchase agreements, and bank accounts with commercial banks with Tier 1 capital exceeding $1 billion, or with an investment grade rating by S&P (LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall have no responsibility or liability for any diminution of the Funds that may result from any deposit or investment made by Computershare in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. Computershare may from time to time receive interest, dividends or other earnings in connection with such deposits or investments. Computershare shall not be obligated to pay such interest, dividends or earnings to the Company, any Holder or any other party.
Section 6.08 Delivery of Warrant Exercise Price. The Warrant Agent shall forward funds received for Warrant exercises in a given month by the fifth (5th ) Business Day of the following month or within one (1) Business Day after written request of the Company by wire transfer to an account designated by the Company.
Section 6.09 Further Assurances. The Company shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may be reasonably required by the Warrant Agent for the carrying out or performing by the Warrant Agent of the provisions of this Agreement.
39
Section 6.10 Force Majeure. Notwithstanding anything to the contrary contained herein, the Company and the Warrant Agent will not be liable for any delays or failures in performance to the extent that they result from acts beyond their reasonable control including, without limitation, acts of God, epidemics, pandemics, terrorist acts (including cyberbreaches of any type of a Party’s electronic information systems), shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest.
Section 6.11 Confidentiality. The Warrant Agent and the Company agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement including the fees for services set forth in the attached schedule shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by law, including, without limitation, pursuant to subpoenas from state, or federal or national government authorities (e.g., in divorce and criminal actions); provided, that for the avoidance of doubt, this Agreement may be filed by the Company with the SEC (without including any fee information).
Article VII
Miscellaneous
Section 7.01 Persons Benefiting. Nothing in this Agreement is intended or shall be construed to confer upon any Person other than the Company, the Warrant Agent and the Holders any right, remedy or claim under or by reason of this Agreement or any part hereof.
Section 7.02 Rights of Holders. Holders of unexercised Warrants, as such, have no rights as shareholders and are not entitled to exercise any rights whatsoever as shareholders of the Company, including, but not limited to the rights to (a) receive dividends or other distributions, (b) receive notice of or vote at any meeting of the shareholders, (c) consent to any action of the shareholders, (d) receive notice of any other proceedings of the Company or (e) exercise any preemptive right.
40
Section 7.03 Notices. Any notice or communication between the parties to this Agreement shall be in writing and delivered in Person or mailed by first-class mail or sent by overnight delivery service, and any such notice or communication shall be deemed given when sent. Notices sent by mail or overnight delivery service as described in this Section 7.03 should be addressed as follows:
if to the Company:
Enovix Corporation
3501 W Warren Avenue
Fremont, California 94538
Attention: General Counsel
and email to: legal@enovix.com
With a copy to:
Arnold & Porter Kaye Scholer LLP
250 West 55th Street
New York, NY 10019
Attention: Michael Penney
and email to: michael.penney@arnoldporter.com
and
Conv-Ex Advisors Limited
80 Coleman Street
London
EC2R 5BJ
United Kingdom
Email: calculation.agent@conv-ex.com
Attention: Calculation Agency Team
if to the Warrant Agent:
Computershare Trust Company N.A.,
Computershare Inc.
150 Royall Street
Canton, MA 02021
Attention: Client Services
with a copy to:
Conv-Ex Advisors Limited
80 Coleman Street
London
EC2R 5BJ
United Kingdom
Email: calculation.agent@conv-ex.com
Attention: Calculation Agency Team
41
The Company or the Warrant Agent each by notice to the other may designate in writing additional or different physical addresses or e-mail addresses for subsequent notices or communications.
Except for any notice which may be given by issuance of a press release pursuant to the terms of this Agreement, any notice or communication mailed to a Holder shall be mailed to the Holder at the Holder’s address as it appears on the Warrant Register, and shall be sufficiently given if so mailed within the time prescribed. Failure to deliver a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other Holders. If a notice or communication is delivered in the manner provided above, it is duly given when sent, whether or not the addressee receives it.
Notwithstanding any other provision of this Agreement, where this Agreement provides for notice of any event to the Holders, such notice shall be sufficiently given to any Holder of a Warrant represented by a Global Warrant if given to the Depositary pursuant to the customary procedures of the Depositary.
Except for any notice which provides for a shorter period pursuant to the terms of this Agreement, any notice delivered pursuant to this Agreement that restricts the ability of a Holder to exercise its Warrant not otherwise described in this Agreement shall only be effective at least five (5) Business Days after the delivery of such notice.
Notwithstanding anything to the contrary herein, issuance by the Company of a press release in accordance with its customary procedures or as prescribed by this Agreement shall satisfy any requirement to provide public notice or notice in writing or by email under this Agreement (except for notices required to be delivered to the Warrant Agent).
Section 7.04 Governing Law. THE LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS AGREEMENT, THE WARRANT CERTIFICATES AND THE WARRANTS. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE WARRANT CERTIFICATES AND THE WARRANTS OR THE TRANSACTIONS CONTEMPLATED HEREBY.
Section 7.05 Successors. All agreements of the Company in this Agreement and the Warrant Certificates shall bind its successors. All agreements of the Warrant Agent in this Agreement shall bind its successors.
Section 7.06 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together constitute one and the same instrument. Counterparts may be delivered via facsimile, PDF, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, including docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A signature to this Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original signature.
42
Section 7.07 Severability. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid, illegal or unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect in that jurisdiction only such clause or provision, or part thereof, and shall not in any manner affect such clause or provision in any other jurisdiction or any other clause or provision of this Agreement in any jurisdiction; provided, however, that if such excluded provision shall materially and adversely affect the rights, immunities, liabilities, duties or obligations of the Warrant Agent, the Warrant Agent shall be entitled to resign immediately upon written notice to the Company.
Section 7.08 Withholding Rights. In the event that the Company, the Warrant Agent or their agents determine that they are obligated to withhold or deduct any tax or other governmental charge under any applicable law on behalf of a Holder (whether upon the distribution of the Warrants under this Agreement, upon any adjustment made pursuant to Article IV, upon exercise or otherwise), the Company, the Warrant Agent or their agents shall be entitled, but not obligated, to deduct and withhold such amount by withholding a portion or all of the Warrants or Warrant Shares otherwise deliverable or by otherwise using any property (including, without limitation, Warrants, Warrant Shares or cash) that would otherwise be delivered to or is owned by such Holder, in each case in such amounts as they deem necessary to meet their withholding obligations, and shall also be entitled, but not obligated, to sell all or a portion of such withheld Warrants, Warrant Shares or such other property of the Holder by public or private sale in such amounts and in such manner as they deem necessary and practicable to pay such taxes and charges. In such case, (i) the Company, the Warrant Agent or their agents, as applicable, shall remit to the applicable tax or other authority the required withholding amount or other charge, and (ii) any withheld amounts (and, if applicable in connection with adjustments pursuant to Article IV, other property) shall be treated for all purposes of this Agreement as having been distributed to the Holders in respect of which such deduction and withholding was made. Each Holder shall submit (and shall at all times be eligible to deliver) to the Company or the Warrant Agent on or prior to the date that it becomes a Holder, a properly executed IRS Form W-9 or appropriate IRS Form W-8, as applicable and any other tax form or certification reasonably requested by the Company or the Warrant Agent to establish an exemption from withholding tax on payments and deliveries hereunder as well as an exemption from, or a reduction in the rate of, U.S. withholding that may apply to any dividend or constructive dividend (e.g., under Section 305(c) of the Internal Revenue Code of 1986, as amended), and, in each case, shall promptly update such form or certification upon reasonable request or if it expires or becomes obsolete or inaccurate in any respect. Notwithstanding any provision to the contrary, the Company, the Warrant Agent or their agents (i) may determine in their reasonable discretion the amount and the timing of any such dividend or constructive dividend and (ii) shall be authorized to take any actions that may be necessary or appropriate to comply with all applicable tax withholding and reporting requirements under applicable law.
43
Section 7.09 Calculations; Calculation Agent. Conv-Ex Advisors Limited shall be the initial Calculation Agent, pursuant and subject to the terms of the Calculation Agency Agreement, dated on or about the date of this Agreement. The Calculation Agent will be responsible for making all calculations and other determinations specified to be made by it under this Agreement and the Warrants, and any calculations and determinations not so specified will be the responsibility of the Company or an Independent Advisor. All calculations and determinations will be made in good faith and, absent manifest error, such calculations and determinations will be final and binding on the Company, the Warrant Agent and the Holders. The Company will provide with reasonable notice a schedule of the calculations and determinations made by the Company, the Calculation Agent or an Independent Advisor, as applicable, to the Warrant Agent. The Warrant Agent is entitled to rely conclusively upon the accuracy of the calculations and determinations made by the Company, the Calculation Agent and any Independent Advisor appointed in accordance with this Agreement without independent verification.
Section 7.10 Limited Responsibility of Calculation Agent and Independent Advisor. The Calculation Agent (and any Independent Advisor appointed in connection with the Warrants) is acting exclusively as an agent for, and upon request by, the Company. Neither the Calculation Agent (acting in such capacity) nor any Independent Advisor appointed in connection with the Warrants (acting in such capacity) shall have any relationship of agency or trust with, or be liable to or shall they incur any liability as against, the Holders or the Warrant Agent.
Section 7.11 Entire Agreement. This Agreement and the Warrant Certificate contain the entire agreement and understanding among the parties hereto with respect to the subject matter hereof, and supersede all prior and contemporaneous agreements, understandings, inducements and conditions, express or implied, oral or written, of any nature whatsoever with respect to the subject matter hereof. Notwithstanding anything to the contrary contained in this Agreement, in the event of an inconsistency between any provision in this Agreement and any provision in a Warrant Certificate, as it may from time to time be amended, the terms of this Agreement shall prevail.
[Signature pages follow]
44
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the date first written above.
| ENOVIX CORPORATION | |||
| By: | /s/ Ryan Benton | ||
| Name: | Ryan Benton | ||
| Title: | Interim Chief Executive Officer | ||
Enovix Corporation – Signature Page to Warrant Agreement
| COMPUTERSHARE INC., and | |||
| COMPUTERSHARE TRUST COMPANY N.A., | |||
| collectively, as Warrant Agent | |||
| By: | /s/ Collin Ekeogu | ||
| Name: | Collin Ekeogu | ||
| Title: | Senior Manager, Corporate Actions | ||
Enovix Corporation – Signature Page to Warrant Agreement
EXHIBIT A
FORM OF WARRANT
[Global Securities Legend]
UNLESS THIS GLOBAL WARRANT IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), NEW YORK, NEW YORK, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
TRANSFERS OF THIS GLOBAL WARRANT SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL WARRANT SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN THE WARRANT AGREEMENT REFERRED TO BELOW.
| No. [ ] | Certificate for [ ] Warrants |
WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF
ENOVIX CORPORATION
THIS CERTIFIES THAT [ ], or its registered assigns, is the registered holder of the number of Warrants set forth above (the “Warrants”). Each Warrant entitles the holder thereof (the “Holder”), at its option and subject to the provisions contained herein and in the Warrant Agreement referred to below, to purchase from Enovix Corporation, a corporation organized under the laws of the State of Delaware (including any successor thereto, the “Company”) a number of shares of common stock, par value of $0.0001 per share, of the Company (the “Common Stock”) equal to the Warrant Exercise Rate (which is initially one (1) at an exercise price of $3.00 per Warrant (subject to amendment from time to time in accordance with Section 4.06 of the Warrant Agreement, the “Warrant Exercise Price”), payable in cash, or, subject to certain conditions, payable using Designated Notes as described in the Warrant Agreement. This Warrant Certificate shall terminate and become void as of the earlier of (x) the Close of Business, on the Expiration Date for the Warrants or (y) upon the exercise hereof as to all the shares of Common Stock subject hereto. The number of shares issuable upon exercise of the Warrants shall be subject to adjustment from time to time as set forth in the Warrant Agreement.
This Warrant Certificate is issued under and in accordance with a Warrant Agreement, dated as of November 18, 2026 (the “Warrant Agreement”), between the Company and Computershare, Inc., a Delaware corporation, and its affiliate, Computershare Trust Company N.A., a federally chartered trust company (together, the “Warrant Agent,” which term includes any successor Warrant Agent under the Warrant Agreement), and is subject to the terms and provisions contained in the Warrant Agreement, to all of which terms and provisions the Holder of this Warrant Certificate consents by acceptance hereof. The Warrant Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to the Warrant Agreement for a full statement of the respective rights, limitations of rights, duties and obligations of the Company, the Warrant Agent and the Holders of the Warrants. In the event of an inconsistency between the terms of this Warrant Certificate and the Warrant Agreement, the terms of the Warrant Agreement shall prevail. The Company shall amend any provisions of the Warrant Certificate in compliance with Section 4.05 or 4.06 of the Warrant Agreement.
Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Warrant Agreement. A copy of the Warrant Agreement may be obtained for inspection by the Holder hereof upon written request to the Warrant Agent, 150 Royall Street, Suite 101, Canton, MA 02021.
Subject to the terms of the Warrant Agreement, the Warrants may be exercised in whole or in part prior to 5:00 p.m., New York City time, on any Business Day (each, an “Exercise Request Date”), in accordance with Section 3.04 of the Warrant Agreement; provided however, that no Warrant shall be exercisable after the Close of Business on the Expiration Date, as it may be adjusted in accordance with the Warrant Agreement. Holders should carefully review the provisions of Section 3.04 of the Warrant Agreement and, if Designated Notes are being used to pay the Warrant Exercise Price, Exhibit B to the Warrant Agreement, for the requirements for a valid exercise of Warrants.
If an Exercise Notice is received or deemed to be received after the Close of Business on the Expiration Date, the exercise thereof will be null and void and any funds delivered to the Warrant Agent will be returned to the Holder as soon as practicable. In no event will interest accrue on funds deposited with the Warrant Agent in respect of an exercise or attempted exercise of Warrants. Any otherwise valid exercise of Warrants submitted after any applicable deadline for exercise may, in the sole and absolute discretion of the Company, be accepted and honored. The Company’s decision with respect to any such exercise shall be determinative.
Notwithstanding the foregoing, holders of Warrants will be able to exercise their Warrants only if the Common Stock Shelf Registration Statement relating to the Warrant Shares is effective and not subject to suspension pursuant to the Warrant Agreement and such securities are qualified for sale or exempt from qualification under the applicable securities laws of any relevant states or other jurisdictions;
Upon any partial exercise of the Warrants, there shall be countersigned and issued to the Holder hereof a new Warrant Certificate representing those Warrants which were not exercised. This Warrant Certificate may be exchanged at the office of the Warrant Agent by presenting this Warrant Certificate properly endorsed with a request to exchange this Warrant Certificate for other Warrant Certificates evidencing an equal number of Warrants. No fractional Warrant Shares will be issued upon the exercise of the Warrants. If any fraction of a Warrant Share would be issuable upon the exercise of Warrants, the Company shall round down the total number of shares of Common Stock to be issued to the relevant Holder to the nearest Whole Number.
All Warrant Shares shall, upon such issue, be duly and validly issued and fully paid and non-assessable.
The Holder in whose name a Warrant Certificate is registered may be deemed and treated by the Company and the Warrant Agent as the absolute owner of the Warrant Certificate for all purposes whatsoever and neither the Company nor the Warrant Agent shall be affected by notice to the contrary.
Holders of Warrants do not have any rights as a stockholder with respect to the shares of Common Stock issuable upon exercise of the Warrants prior to the time such Warrants are validly exercised in accordance with all the terms and conditions of the Warrant Agreement, and the Warrant Exercise Price is paid.
[Signature page follows]
This Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Warrant Agent.
| ENOVIX CORPORATION | |||
| By: | |||
| Name: | Ryan Benton | ||
| Title: | Interim Chief Executive Officer | ||
DATED: November 18, 2026
Countersigned:
COMPUTERSHARE INC., and
COMPUTERSHARE TRUST COMPANY N.A.,
collectively, as Warrant Agent
| By: | ||
| Name: | ||
| Title: |
FORM OF ELECTION TO PURCHASE WARRANT SHARES
(to be executed only upon exercise of Warrants (other than any Electronic Exercise))
ENOVIX CORPORATION
The undersigned hereby irrevocably elects to exercise the number of Warrants set forth below, each of which entitles the holder to purchase a number of shares of Common Stock, par value $0.0001 per share, of Enovix Corporation equal to the Warrant Exercise Rate in effect on the Exercise Date, at an exercise price of $3.00 per Warrant (the “Warrant Exercise Price”), payable in cash or, if there are Designated Notes as of the date of this Election, Designated Notes on the terms and conditions specified in the Warrant Certificate and the Warrant Agreement therein referred to, surrenders all right, title and interest in the number of Warrants exercised hereby to Enovix Corporation and directs that the shares of Common Stock deliverable upon the exercise of such Warrants, and interests in any Global Warrant or Definitive Warrant representing unexercised Warrants, be registered or placed in the name and at the address specified below and delivered thereto. If other than the registered holder of the Warrants, the undersigned must pay all transfer or similar taxes, assessments or similar governmental charges in connection with any exercise of such Warrants. Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Warrant Agreement. For the protocol for exercise of Warrants with payment in Designated Notes, see Section 3.04 of the Warrant Agreement and Exhibit B to the Warrant Agreement.
A. Number of Warrants exercised hereby: _____________
B. Warrant Exercise Price (if exercise is paid by cash): $3.00
C. DN Warrant Exercise Price (if exercise is paid by Designated Notes): $1,000 principal amount of Designated Notes to exercise up to 333 Warrants
D. Warrant Exercise Price being paid by:
☐ Cash
☐ Designated Notes
E. (if exercise is paid by cash) Aggregate Warrant Exercise Price in respect of number of Warrants exercised: $_____________ (= A x B)
Amount of Cash Delivered: $________________
F. (if exercise is paid by Designated Notes) Aggregate DN Warrant Exercise Price in respect of number of Warrants exercised hereby with Designated Notes $_____________ (= N x $1,000, where N = A / 333, and (if A is not a whole multiple of 333) rounded up to the nearest Whole Number1 )
Aggregate Principal Amount of Designated Notes Delivered: $________________
Excess Aggregate Principal Amount of Designated Notes Delivered to be returned (if any): $________________
| 1 | e.g.: |
| ● | if
A = number of Warrants exercised = 500, then A / 333 = 500 / 333 = 1.502…, and therefore N = 2 and Aggregate DN Warrant Exercise Price = N x $1,000 = 2 x $1,000 = $2,000; | |
| ● | if
A = number of Warrants exercised = 1,000, then A / 333 = 1,000 / 333 = 3.003…, and therefore N = 4 and Aggregate DN Warrant Exercise Price = N x $1,000 = 4 x $1,000 = $4,000 | |
| ● | if
A = number of Warrants exercised = 2,750, then A / 333 = 2,750 / 333 = 8.258…, and therefore N = 9 and Aggregate DN Warrant Exercise Price = N x $1,000 = 9 x $1,000 = $9,000 | |
| ● | etc. |
| Date: _____________ | |
| (Name of Owner) | |
| (Signature of Owner)2 | |
| (Street Address) | |
| (City) (State) (Zip Code) |
Securities to be issued to:
If held in book-entry form through the Depositary:
Depositary Account Number:
Name of Agent Member:
If in definitive or uncertificated form:
Social security or identifying number:
Name:
Street Address:
City, State and Zip Code:
Any unexercised Warrants evidenced by the exercising Holder’s interest in the applicable Global Warrant or Definitive Warrant, as the case may be, to be issued to:
If in book-entry form through the Depositary:
Depositary Account Number:
Name of Agent Member:
If in definitive form:
Social security or identifying number:
Name:
Street Address:
City, State and Zip Code:
| 2 | The signature must correspond with the name as written upon the face of the within Warrant Certificate in every particular, without alteration or enlargement or any change whatsoever. |
SCHEDULE OF DTC DWAC Withdrawal of Designated Notes
Designated Notes used to pay the DN Warrant Exercise Price (only applicable if exercised when a series of notes are designated by the Company):
If held in book-entry form through the Depositary:
| DTC Participant Name | DTC Participant Number | Title of Designated Notes | CUSIP of Designated Notes | Principal Amount of Designated Notes Surrendered | |||||
FORM OF WARRANT TRANSFER
For value received, the undersigned hereby sells, assigns and transfers unto ___________ the right to purchase [ ] Warrant Shares representing shares of Common Stock, par value $0.0001 per share, of Enovix Corporation. (the “Company”) pursuant to the attached Warrant Certificate and does hereby irrevocably constitute and appoint ______________________attorney to transfer the Warrant, or such portion as is transferred hereby, on the books of the Company with full power of substitution in the premises. The undersigned requests said attorney to issue to the transferee a Warrant Certificate evidencing such transfer and to issue to the undersigned a new Warrant Certificate evidencing the right to purchase Warrant Shares for the balance not so transferred, if any.
| Date: _____________ | |
| (Signature of Owner)3 | |
| (Street Address) | |
| (City) (State) (Zip Code) | |
|
Medallion Guarantee by: |
| Name in which new Warrant(s) should be registered: | |
| (Name) | |
| (Street Address) | |
| (City) (State) (Zip Code) | |
| (social security or identifying number) | |
| 3 | The signature must correspond with the name as written upon the face of the within Warrant Certificate in every particular, without alteration or enlargement or any change whatsoever, and must be medallion guaranteed by an eligible guarantor institution. |
SCHEDULE OF INCREASES OR DECREASES IN GLOBAL WARRANT4
The initial number of Warrants represented by this Global Warrant is [ ].
The following increases or decreases in this Global Warrant have been made:
| Date of Exercise or Exchange |
Decrease in number of Warrants in this Global Warrant Certificate |
Increase in number of Warrants in this Global Warrant Certificate |
Number of Warrants in this Global Warrant Certificate following such change |
Signature of authorized officer of Warrant Agent |
|||||
| 4 | To be included only if Warrants are in global form. |
EXHIBIT B
Protocol for Exercise of Warrants with Designated Notes
For both exercise through DWAC and Electronic Exercise, the treatment of accrued but unpaid interest on Designated Notes surrendered through this protocol will be governed by Section 3.04 of the Warrant Agreement and this Exhibit B. Notwithstanding anything to the contrary contained in this Exhibit B, in the event of inconsistency between any provision in this Exhibit B and any provision in the Warrant Agreement, as it may from time to time be amended, with respect to the rights, duties, obligations, liabilities and immunities of the Warrant Agent, the terms of the Warrant Agreement shall prevail.
Protocol for Exercise of Warrants with Payment in Designated Notes – DWAC
| 1. | The Holder shall electronically (via e-mail to USCASubmissions@computershare.com) submit the applicable form of election included in Exhibit A to the Warrant Agent, indicating whether the Holder desires to tender payment for the exercise of the Warrant(s) in one or more series of Designated Notes. |
| 2. | The Holder or the relevant Agent Member shall use the Depositary’s Deposit/Withdrawal at Custodian (“DWAC”) system to (a) withdraw the Holder’s beneficial interest in the Warrants being exercised and transfer such Warrants to the Warrant Agent, (b) withdraw the Designated Notes being surrendered from their book-entry accounts with the Depositary and transfer such Designated Notes to the applicable trustee under the indenture governing the terms of such Designated Notes and (c) submit a deposit request to receive shares of Common Stock of the Company from the Warrant Agent. If the Designated Notes being surrendered are not held in global form through the Depositary, then such Designated Notes shall be transferred to the applicable trustee pursuant to the applicable procedures of the trustee, registrar or transfer agent, as applicable, under the indenture governing the terms of such Designated Notes. |
| 3. | Designated Notes shall be surrendered in whole multiples of $1,000 principal amount. |
| 4. | The Warrant Agent shall confirm that the aggregate principal amount of the Designated Notes surrendered by the Holder is sufficient to pay for the DN Warrant Exercise Price in respect of the number of Warrants being exercised, as determined in accordance with Section 3.04(a) of the Warrant Agreement. |
| 5. | Once confirmed, the Warrant Agent shall provide the Depositary with any confirmations or acknowledgments reasonably necessary for the transfers of the Warrants and Designated Notes described in step 2 above to occur. The relevant trustee will approve the DWAC from the Holder pursuant to instructions by the Company to the trustee. |
| 6. | Following the transfers of the Designated Notes and Warrants described above, the Warrant Agent shall approve the DWAC from the Holder to transfer the Warrant Shares pursuant to the exercise of the Warrants to the relevant Agent Member through the Depositary’s DWAC system pursuant to Article III of the Warrant Agreement. |
| 7. | All Warrants transferred to the Warrant Agent and Designated Notes surrendered to the trustee under the relevant indenture, as applicable, pursuant to this protocol shall be cancelled. The relevant trustee will receive written instructions from the Company to accept the DWACs from the Holders. |
| 8. | If the principal amount of one or more series of Designated Notes surrendered to exercise Warrants is in excess of the principal amount required to be surrendered pursuant to Sections 3.04(a) and (d) of the Warrant Agreement to exercise the number of Warrants so exercised, as determined by the Company in accordance with Section 3.04, the Company will only return such excess principal amount as is required by Section 3.04(d) of the Warrant Agreement. |
| 9. | Any accrued but unpaid interest on any Designated Notes surrendered to exercise Warrants shall be forfeited by the Holder surrendering such Designated Notes, except as provided in the following sentence of this paragraph. Notwithstanding the foregoing, if a Designated Note is surrendered after a record date and on or before the immediately succeeding interest payment date with respect to such Designated Note, interest will be paid with respect to the principal balance of the Designated Note as of the record date in accordance with the applicable indenture for such Designated Note. |
Protocol For Electronic Exercise of Warrants With Designated Notes – Electronic Exercise
| 1. | The Holder or the relevant Agent Member shall submit the electronic exercise (“Electronic Exercise”) through the Warrant Exercise ATOP event and the Designated Note ATOP event. The related instructions shall be submitted in the sequence and linked using the Voluntary Offer Instruction number (“VOI”) matching convention specified in the final DTC event announcements. |
| 2. | Designated Notes shall be surrendered in whole multiples of $1,000 principal amount in an amount sufficient to pay the DN Warrant Exercise Price in respect of the number of Warrants being exercised. |
| 3. | DTC will record each ATOP instruction and debit the Warrants and Designated Notes submitted on the Exercise Request Date. |
| 4. | The Warrant Agent shall review and reconcile the related Warrant and Designated Note instructions using the ATOP files and VOIs for the weekly cycle and confirm compliance with the required exercise ratio and other applicable requirements. |
| 5. | For each weekly cycle for instructions submitted by 5:00 p.m. New York City time on Tuesdays, the Warrant Agent shall provide DTC with the acceptance, rejection and allocation instructions one Business Day before the applicable Allocation Date (as set out in Exhibit C). These instructions shall identify the related VOIs, the applicable Warrant Exercise Rate and the accrued interest rate confirmed by reference to Exhibit C to the Warrant Agreement. The weekly submission window, Allocation Dates and applicable deadlines will be specified in the final DTC event announcements. |
| 6. | On the Allocation Date, DTC will process accepted exercises, draw down the accepted securities, credit the resulting Warrant Shares to the relevant Agent Member and distribute accrued interest, subject to the required approvals from the Warrant Agent, the applicable trustee and applicable transfer agent or FAST agent. The Company shall calculate the aggregate accrued interest payable and the Warrant Agent shall remit the necessary funds provided by the Company to DTC. The Company shall cause the Warrant Shares to be issued in accordance with Section 3.05 of the Warrant Agreement. |
| 7. | If an electronic exercise is unmatched, incomplete or otherwise noncompliant, the Warrant Agent will instruct DTC to reject it. DTC will return the affected Warrants and Designated Notes and notify the relevant Agent Member through its systems. Rejected instructions will not constitute an exercise or be partially accepted, and no submitted principal will be forfeited. The Holder may correct and resubmit instructions during a subsequent submission period or use the manual exercise procedures, subject to the applicable deadlines under the Warrant Agreement. |
| 8. | All Warrants and Designated Notes surrendered pursuant to an accepted electronic exercise shall be cancelled. The Warrant Agent shall update the Warrant Register and its related records to reflect the Warrants exercised and the Warrant Shares issued, and the applicable registrar, transfer agent or trustee shall update the records for the Designated Notes in accordance with the relevant indenture and its procedures. |
| 9. | Warrants exercised with Designated Notes shall be entitled to a cash amount per each $1,000 in principal amount of such Designated Notes equal to the Accrued Interest Amount as set forth on Exhibit C. |
EXHIBIT C
Allocation Dates
in respect of the relevant Designated Notes (Electronic Exercise) Surrender Date
AND
Accrued Interest Amount
in respect of the relevant Designated Notes (Electronic Exercise) Surrender Date
(per each US$1,000 in principal amount of the 2028 Notes
surrendered for the relevant Electronic Exercise of Warrants)
=
$1,000 *
Accrued rate for such Designated Notes (Electronic Exercise) Surrender Date
(as set out in the table below)
| Designated Notes (Electronic Exercise) Surrender Date falling in the period | Accrued rate (%) |
Allocation Date5 | Designated Notes (Electronic Exercise) Surrender Date falling in the period | Accrued rate (%) |
Allocation Date 5 | |||||||||||
| from (and including) | to (and including) | from (and including) | to (and including) | |||||||||||||
| November 18, 2026 | November 24, 2026 | 0.225 | November 27, 2026 | August 11, 2027 | August 17, 2027 | 0.908 | August 19, 2027 | |||||||||
| November 25, 2026 | December 1, 2026 | 0.275 | December 3, 2026 | August 18, 2027 | August 24, 2027 | 0.967 | August 26, 2027 | |||||||||
| December 2, 2026 | December 8, 2026 | 0.333 | December 10, 2026 | August 25, 2027 | August 31, 2027 | 1.017 | September 2, 2027 | |||||||||
| December 9, 2026 | December 15, 2026 | 0.392 | December 17, 2026 | September 1, 2027 | September 7, 2027 | 1.075 | September 9, 2027 | |||||||||
| December 16, 2026 | December 22, 2026 | 0.450 | December 24, 2026 | September 8, 2027 | September 14, 2027 | 1.133 | September 16, 2027 | |||||||||
| December 23, 2026 | December 29, 2026 | 0.500 | December 31, 2026 | September 15, 2027 | September 21, 2027 | 1.192 | September 23, 2027 | |||||||||
| December 30, 2026 | January 5, 2027 | 0.558 | January 7, 2027 | September 22, 2027 | September 28, 2027 | 1.250 | September 30, 2027 | |||||||||
| January 6, 2027 | January 12, 2027 | 0.617 | January 14, 2027 | September 29, 2027 | October 5, 2027 | 1.308 | October 7, 2027 | |||||||||
| January 13, 2027 | January 19, 2027 | 0.675 | January 21, 2027 | October 6, 2027 | October 12, 2027 | 1.367 | October 14, 2027 | |||||||||
| January 20, 2027 | January 26, 2027 | 0.733 | January 28, 2027 | October 13, 2027 | October 15, 2027 | 1.425 | October 21, 2027 | |||||||||
| January 27, 2027 | February 2, 2027 | 0.783 | February 4, 2027 | October 18, 2027 | October 19, 2027 | 0.00 | 6 | October 21, 20277 | ||||||||
| February 3, 2027 | February 9, 2027 | 0.842 | February 11, 2027 | October 20, 2027 | October 26, 2027 | 0.00 | 6 | October 28, 20277 | ||||||||
| February 10, 2027 | February 16, 2027 | 0.900 | February 18, 2027 | October 27, 2027 | October 29, 2027 | 0.00 | 6 | November 4, 20277 | ||||||||
| February 17, 2027 | February 23, 2027 | 0.958 | February 25, 2027 | November 1, 2027 | November 2, 2027 | 0.033 | November 4, 2027 | |||||||||
| February 24, 2027 | March 2, 2027 | 1.033 | March 4, 2027 | November 3, 2027 | November 9, 2027 | 0.100 | November 12, 2027 | |||||||||
| March 3, 2027 | March 9, 2027 | 1.092 | March 11, 2027 | November 10, 2027 | November 16, 2027 | 0.150 | November 18, 2027 | |||||||||
| March 10, 2027 | March 16, 2027 | 1.150 | March 18, 2027 | November 17, 2027 | November 23, 2027 | 0.217 | November 26, 2027 | |||||||||
| March 17, 2027 | March 23, 2027 | 1.208 | March 25, 2027 | November 24, 2027 | November 30, 2027 | 0.267 | December 2, 2027 | |||||||||
| March 24, 2027 | March 30, 2027 | 1.258 | April 1, 2027 | December 1, 2027 | December 7, 2027 | 0.325 | December 9, 2027 | |||||||||
| March 31, 2027 | April 6, 2027 | 1.317 | April 8, 2027 | December 8, 2027 | December 14, 2027 | 0.383 | December 16, 2027 | |||||||||
| April 7, 2027 | April 13, 2027 | 1.375 | April 15, 2027 | December 15, 2027 | December 21, 2027 | 0.442 | December 23, 2027 | |||||||||
| April 14, 2027 | April 15, 2027 | 1.433 | April 22, 2027 | December 22, 2027 | December 28, 2027 | 0.500 | December 30, 2027 | |||||||||
| April 16, 2027 | April 20, 2027 | 0.00 | 6 | April 22, 20277 | December 29, 2027 | January 4, 2028 | 0.550 | January 6, 2028 | ||||||||
| April 21, 2027 | April 27, 2027 | 0.00 | 6 | April 29, 20277 | January 5, 2028 | January 11, 2028 | 0.608 | January 13, 2028 | ||||||||
| April 28, 2027 | April 30, 2027 | 0.00 | 6 | May 6, 20277 | January 12, 2028 | January 18, 2028 | 0.667 | January 20, 2028 | ||||||||
| May 3, 2027 | May 4, 2027 | 0.050 | May 6, 2027 | January 19, 2028 | January 25, 2028 | 0.725 | January 27, 2028 | |||||||||
| May 5, 2027 | May 11, 2027 | 0.108 | May 13, 2027 | January 26, 2028 | February 1, 2028 | 0.775 | February 3, 2028 | |||||||||
| May 12, 2027 | May 18, 2027 | 0.167 | May 20, 2027 | February 2, 2028 | February 8, 2028 | 0.833 | February 10, 2028 | |||||||||
| May 19, 2027 | May 25, 2027 | 0.225 | May 27, 2027 | February 9, 2028 | February 15, 2028 | 0.892 | February 17, 2028 | |||||||||
| May 26, 2027 | June 1, 2027 | 0.275 | June 3, 2027 | February 16, 2028 | February 22, 2028 | 0.950 | February 24, 2028 | |||||||||
| June 2, 2027 | June 8, 2027 | 0.333 | June 10, 2027 | February 23, 2028 | February 29, 2028 | 1.017 | March 2, 2028 | |||||||||
| June 9, 2027 | June 15, 2027 | 0.392 | June 17, 2027 | March 1, 2028 | March 7, 2028 | 1.075 | March 9, 2028 | |||||||||
| June 16, 2027 | June 22, 2027 | 0.450 | June 24, 2027 | March 8, 2028 | March 14, 2028 | 1.133 | March 16, 2028 | |||||||||
| June 23, 2027 | June 29, 2027 | 0.508 | July 1, 2027 | March 15, 2028 | March 21, 2028 | 1.192 | March 23, 2028 | |||||||||
| June 30, 2027 | July 6, 2027 | 0.567 | July 8, 2027 | March 22, 2028 | March 28, 2028 | 1.250 | March 30, 2028 | |||||||||
| July 7, 2027 | July 13, 2027 | 0.625 | July 15, 2027 | March 29, 2028 | April 4, 2028 | 1.300 | April 6, 2028 | |||||||||
| July 14, 2027 | July 20, 2027 | 0.683 | July 22, 2027 | April 5, 2028 | April 11, 2028 | 1.358 | April 13, 2028 | |||||||||
| July 21, 2027 | July 27, 2027 | 0.742 | July 29, 2027 | April 12, 2028 | April 14, 2028 | 1.417 | April 20, 2028 | |||||||||
| July 28, 2027 | August 3, 2027 | 0.792 | August 5, 2027 | April 17, 2028 | April 18, 2028 | 0.00 | 6 | April 20, 20287 | ||||||||
| August 4, 2027 | August 10, 2027 | 0.850 | August 12, 2027 | April 19, 2028 | April 25, 2028 | 0.00 | 6 | April 27, 20287 | ||||||||
| April 26, 2028 | April 28, 2028 | 0.00 | 6 | May 4, 20287 | ||||||||||||
| 5 | If the relevant date set forth in the table as being the Allocation Date is not a Business Day, such Allocation Date shall instead be the following Business Day (provided that in any such case the accrued rate for such Allocation Date (and consequently, the applicable Accrued Interest Amount) shall not be adjusted in respect of such postponement of such Allocation Date and shall remain as set out in the table above for the date which (but for such postponement) would have been the Allocation Date). |
| 6 | If the Designated Notes (Electronic Exercise) Surrender Date (such Designated Notes (Electronic Exercise) Surrender Date, a “Full Coupon Designated Notes (Electronic Exercise) Surrender Date”) in respect of a 2028 Note falls after the Regular Record Date (as defined in the 2028 Indenture) (being April 15 and October 15 immediately preceding the applicable Interest Payment Date, respectively) in respect of any Interest Payment Date (as defined in the 2028 Indenture) (being May 1 and November 1 of each year) and before such Interest Payment Date: |
| (i) | payment of such interest will be made on such Interest Payment Date to Cede & Co (as nominee of DTC as depositary of the global note representing such 2028 Note) as holder of record of such 2028 Note on such Regular Record Date, all in accordance with and subject to the 2028 Indenture, and Cede & Co (as nominee of DTC as depositary of the global note representing such 2028 Note) and the Company have agreed that the relevant beneficial owner of such 2028 Note to which such Full Coupon Designated Notes (Electronic Exercise) Surrender Date shall be entitled to receive such interest (being the full amount of the coupon due on the relevant Interest Payment Date, i.e., $15.00 per each $1,000 in principal amount of such 2028 Note) on the relevant Interest Payment Date; and | |
| (ii) | therefore, no Accrued Interest Amount shall be required to be paid in respect of the 2028 Note so surrendered on such Full Coupon Designated Notes (Electronic Exercise) Surrender Date. |
| 7 | Allocation Date relevant for the delivery of the Warrant Shares only for such Designated Notes (Electronic Exercise) Surrender Date (which is a Full Coupon Designated Notes (Electronic Exercise) Surrender Date in respect of which no Accrued Interest Amount is payable in accordance with and subject to note 6 above). |
Exhibit 5.1
November 18, 2026
| Enovix Corporation 3501 W. Warren Avenue Fremont, CA 94538 |
| Re: Enovix Corporation - Registration Statement on Form S-3 (File No. 333-299760) |
Ladies and Gentlemen:
We have examined the Registration Statement on Form S-3, File No. 333-299760, of Enovix Corporation, a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), in connection with the issuance and sale by the Company of up to 62,329,657 shares of the Company’s common stock, par value $0.0001 per share, (the “Shares”) upon the exercise of warrants issued by the Company pursuant to a warrant agreement between the Company and Computershare Inc., and its affiliate, Computershare Trust Company, N.A., dated November 18, 2026 (the “Warrant Agreement”).
This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act.
In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of specimen warrant certificates, the Warrant Agreement, the Registration Statement and the prospectus contained therein and the prospectus supplement dated November 18, 2026 relating to the issuance of the Shares (the “Prospectus Supplement”) and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies, the authenticity of the originals of such latter documents, that all parties to such documents (other than the Company) had the power, corporate or other, to enter into and perform all obligations thereunder, that all such documents have been duly authorized by all requisite action, corporate or other, and duly executed and delivered by all parties thereto (other than the Company) and that all such documents constitute the valid and binding obligation of each party thereto (other than the Company) enforceable against each such party in accordance with their terms. As to any facts material to the opinions expressed herein that we did not independently establish or verify, we have relied upon oral or written statements and representations of officers and other representatives of the Company and others.
Arnold & Porter Kaye Scholer LLP
250 West 55th Street | New York, NY 10019-9710 | www.arnoldporter.com
Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor as set forth in the Warrant Agreement, will be validly issued, fully paid and non-assessable.
The opinions expressed herein are based solely upon the General Corporation Law of the State of Delaware (including the statutory provisions contained therein, the applicable rules and regulations underlying these provisions and reported judicial decisions interpreting the foregoing). We express no opinion herein as to any other laws, statutes, rules, regulations or ordinances.
The opinions set forth above are limited to the matters expressly set forth herein, and no opinion is implied or may be inferred beyond the matters expressly stated. The foregoing opinions are rendered as of the date hereof, and we assume no obligation to update such opinions to reflect any acts, events, facts or circumstances occurring after the date hereof or which may hereafter come to our attention, or any change in the law which may hereafter occur.
We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption “Legal Matters” in the Registration Statement and the prospectus that forms a part thereof and the Prospectus Supplement. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.
| Very truly yours, | |
| /s/ Arnold & Porter Kaye Scholer LLP | |
| Arnold & Porter Kaye Scholer LLP |
Exhibit 99.1
Enovix Distributes Dividend of Warrants to Stockholders
FREMONT, Calif., November 18, 2026 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix” or the “Company,” Nasdaq: ENVX), a developer and manufacturer of advanced lithium-ion batteries, today announced that it will distribute warrants to purchase Enovix common stock (“Warrants”) to its stockholders and certain convertible noteholders on November 18, 2026 (the “Distribution Date”), in accordance with the previously declared stockholder warrant dividend. As previously announced, each stockholder of record as of the close of business on November 13, 2026 (the “Record Date”) will receive one (1) Warrant for every four (4) shares of Enovix common stock held, rounded down to the nearest whole Warrant.
“Our first warrant dividend in 2025 demonstrated the strong support of our stockholders and their interest in participating directly in Enovix’s growth,” said Ryan Benton, Interim Chief Executive Officer. “This distribution builds on that by giving investors another way to participate while helping us address our outstanding debt by permitting Warrant exercises with the delivery of our 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”). Accepting our 2028 Notes at face value as payment of the exercise price allows us to retire debt and preserve cash for the business, while cash exercises provide additional funding that we could also apply toward retiring outstanding 2028 Notes and preserving flexibility to support execution on our priorities.”
Warrant Terms
Eligibility: Stockholders must have purchased or held shares no later than November 12, 2026 to be a stockholder of record as of the close of business on the November 13, 2026 Record Date and to receive Warrants.
Convertible Noteholders: Holders of our 2028 Notes and our 4.75% Convertible Senior Notes due 2030 (the “2030 Notes”) as of the Record Date will also receive Warrants on a pass-through basis, as provided under the applicable indentures, at the same one-for-four ratio.
Receipt of Warrants: Eligible recipients do not need to take any action or make any payment to receive their Warrants. Holders may exercise, hold or sell the Warrants. Holders whose securities are held through an intermediary should contact that intermediary with questions about when the Warrants will appear in their accounts.
Cash Exercise Price: Each Warrant entitles the holder to purchase one (1) share of Enovix common stock for $3.00 in cash, subject to adjustments and amendments under the warrant agreement.
Note Exercise Alternative: In lieu of cash, holders may exercise 333 Warrants by delivering $1,000 principal amount of 2028 Notes. Unless otherwise permitted by Enovix, the 2030 Notes may not be used to exercise the Warrants.
Listing: The Warrants are expected to begin trading separately from Enovix common stock on Nasdaq under the symbol ENVXW on November 19, 2026, subject to applicable approvals.
Scheduled Expiration: April 28, 2028, at 5:00 p.m. New York City time, subject to early expiration and any extension under the warrant agreement.
Early Expiration Price Condition: This condition will be satisfied if the daily volume-weighted average price (“VWAP”) of Enovix common stock equals or exceeds 110% of the then-applicable exercise price, initially $3.30, on twenty (20) trading days within any thirty (30) consecutive trading-day period following issuance (the “Early Expiration Price Condition”). The qualifying trading days need not be consecutive.
If the Early Expiration Price Condition is satisfied, the Warrants will expire at 5:00 p.m. New York City time on the business day immediately following the final qualifying trading day, or a later date selected by the Company in accordance with the warrant agreement. Enovix will announce the applicable expiration date by press release.
Exercise Using Cash or 2028 Notes
Beginning on the Distribution Date, holders may exercise their Warrants using cash or 2028 Notes, subject to the warrant agreement.
The 2028 Notes are designated as eligible for exercise. The 2030 Notes are not eligible and may not be delivered as payment. The Company may, in its discretion and subject to the notice requirements and other terms of the warrant agreement, change the debt securities designated as eligible for exercise.
For cash exercises, each Warrant entitles the holder to purchase one (1) share of Enovix common stock for $3.00. For exercises using 2028 Notes, holders may deliver $1,000 principal amount of 2028 Notes for every 333 Warrants exercised and receive 333 shares. Note exercises must be submitted in whole multiples of this ratio, regardless of the market price of the 2028 Notes.
For example, a holder delivering $20,000 principal amount of 2028 Notes may exercise 6,660 Warrants and receive 6,660 shares of common stock.
The ability to exercise Warrants with 2028 Notes is available to any investor holding 333 Warrants for each $1,000 principal amount of 2028 Notes delivered. Warrants may be acquired through the dividend distribution or in the open market. Any investor may purchase additional Warrants in the market for exercise, and certain qualifying investors may purchase additional 2028 Notes in market transactions.
Any 2028 Notes delivered and accepted for exercise of Warrants will be cancelled, reducing Enovix’s outstanding debt and associated future interest obligations without requiring the Company to use cash to repay that principal. Enovix will receive cash proceeds only from cash exercises of the Warrants. Any cash proceeds will be available for general corporate purposes, including retiring 2028 Notes.
2
Exercise Procedures and Investor Resources
Holders whose Warrants or 2028 Notes are held through a broker, bank or other intermediary should contact that intermediary regarding receipt of their Warrants, exercise instructions, permitted payment methods and applicable deadlines.
The early expiration feature could substantially shorten the exercise period. Holders should make arrangements with their intermediaries in advance, as intermediaries may impose deadlines earlier than the Company’s deadline. Warrants not exercised before the applicable expiration deadline will expire without value.
The warrant agreement, prospectus supplement and related investor materials describe the complete terms, including exercise procedures, adjustments to the Warrants, any exercise suspension provisions and the conditions governing early expiration. The warrant agreement and related registration documents were filed with the U.S. Securities and Exchange Commission (“SEC”) on November 18, 2026.
Additional information, including frequently asked questions, is available on the Company’s Investor Relations website at https://ir.enovix.com.
Transaction Advisors
B. Dyson Capital Advisors is serving as exclusive advisor to the Company on the structuring and distribution of the Warrants.
About Enovix
Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.
Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia, serving customers globally. For more information visit https://enovix.com and follow us on LinkedIn.
No Offer or Solicitation
This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
3
The issuance of the Warrants has not been registered under the Securities Act of 1933, as amended (the “Securities Act”), as the distribution of a Warrant for no consideration does not constitute a sale of a security under Section 2(a)(3) of the Securities Act. A registration statement on Form 8-A describing the terms of the Warrants, and a registration statement on Form S-3 and prospectus supplement relating to the issuance of shares of common stock upon exercise of the Warrants, have been filed with the SEC, and are available on the SEC’s website at www.sec.gov. Holders should read these materials carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the Warrants. Please read the warrant agreement as it will contain important information about the terms of the Warrants.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding: the terms of the Warrants, including the ability to exercise Warrants using cash or 2028 Notes and the scheduled expiration date and the Early Expiration Price Condition; the expected listing of the Warrants on Nasdaq and the existence of a trading market for the Warrants; the number of Warrants that may be exercised and the payment method holders may select; and the anticipated benefits to our balance sheet, interest obligations and liquidity of the Warrant distribution, as well as the anticipated use of additional funding that may be raised through cash exercises of the Warrants to support execution on our priorities. These statements are based on the current expectations of our management, are not predictions of actual performance, and actual results may differ materially from the future results, performance or achievements expressed or implied by the forward-looking statements.
Risks, uncertainties and assumptions that could cause actual results to differ materially from the results and events anticipated by such forward-looking statements include, but are not limited to: the possibility that few or no Warrants are exercised, or that holders elect to exercise Warrants primarily for cash or primarily with 2028 Notes (or the possibility that holders of 2028 Notes do not exercise Warrants by delivering 2028 Notes), such that the cash proceeds received or the debt retired differ materially from our expectations; the possibility that the Warrants are not approved for listing on Nasdaq or that an active trading market for the Warrants does not develop; the possibility that the Warrants expire without value, including because holders are unable to complete an exercise before any accelerated expiration deadline; volatility in the trading price of our common stock and the Warrants, including the possibility that the Early Expiration Price Condition is satisfied earlier or later than anticipated or not at all; and other risks described in the disclosures contained in our filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our annual report on Form 10-K and quarterly reports on Form 10-Q, and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at https://ir.enovix.com and at www.sec.gov. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact
Monica Gould
Blueshirt Group
ir@enovix.com
4
Exhibit 99.2
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
● WARRANT DIVIDEND DISTRIBUTION
Stockholder FAQ
Frequently asked questions about the Enovix warrant dividend
Enovix Corporation (Nasdaq: ENVX) is distributing warrants to its stockholders and convertible noteholders at no cost. This FAQ explains what the warrants are, who receives them, how they can be exercised or sold, and what to expect between the record date and expiration. It is a summary only; the warrant agreement and our filings with the Securities and Exchange Commission (“SEC”) will govern.
● KEY TERMS AT A GLANCE
| EXERCISE PRICE | DISTRIBUTION RATIO |
| $3.00 per share | 1 warrant per 4 shares |
| RECORD DATE | DISTRIBUTION DATE |
| Friday, November 13, 2026 | Wednesday, November 18, 2026 |
| FIRST TRADING DAY | NASDAQ TICKER |
| Thursday, November 19, 2026 | ENVXW |
| EXPIRATION DATE | EARLY EXPIRATION TRIGGER |
| April 28, 2028 | $3.30 VWAP, 20 of 30 trading days |
● IN THIS DOCUMENT
| 01 The Basics | 02 How This Distribution Compares with 2025 | 03 Receiving Your Warrants | ||
| 04 Exercise Price, Expiration and Early Expiration | 05 Exercising Your Warrants | 06 Trading the Warrants | ||
| 07 Why This Structure | 08 Tax Considerations | 09 Other Questions |
01 THE BASICS
What is a Warrant?
A warrant is an option to buy common shares issued directly by a company. Like any option, it gives the holder the right, but not the obligation, to purchase a share of common stock at a specified price (called the “exercise price”) before the warrant expires.
What is a Warrant Dividend?
A warrant dividend is the process of distributing warrants on a pro rata basis to our existing stockholders and convertible noteholders.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 1 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Why is Enovix issuing these Warrants?
Enovix believes that a warrant dividend distribution is a stockholder-aligned approach to strengthening its balance sheet while giving existing stockholders and noteholders the opportunity to participate in the related equity issuance. Recipients can choose to exercise, hold or sell their warrants.
Building on the Company’s successful 2025 warrant dividend program, this distribution adds the ability to exercise warrants using the Company’s 3.00% Convertible Senior Notes due 2028 (the “2028 Notes”) at face value. 2028 Notes surrendered upon exercise will be cancelled, reducing outstanding debt and associated future interest obligations without requiring Enovix to use cash to repay that principal.
Cash exercises would provide additional liquidity for general corporate purposes. Together, these alternatives provide a path to retiring the 2028 Notes and cash generation while preserving cash for the business and putting the participation decision in each holder’s hands.
Who will receive the Warrants?
Holders of Enovix common stock as of the record date, November 13, 2026 (“stockholders”), will receive one warrant for every four (4) shares of common stock held, rounded down to the nearest whole number. No fractional warrants will be issued.
Holders of the 2028 Notes and the 4.75% Convertible Senior Notes due 2030 (the “2030 Notes”) as of the record date (“noteholders”) will also receive warrants on an as-converted pass-through basis in accordance with the terms of the governing agreements. As an example, holders of each $1,000 face amount of 2028 Notes will receive approximately 16 warrants, and holders of each $1,000 face amount of the 2030 Notes will receive approximately 22 warrants, in each case rounded down to the nearest whole number for any fractional warrant. No fractional warrants will be issued. Given this pass-through, the warrant distribution will not trigger a further adjustment to the conversion rate for the convertible notes.
When will the Warrants be distributed?
The Company expects to distribute the warrants to stockholders and noteholders on or about November 18, 2026 (the “distribution date”).
How many Warrants will be issued in total?
Including the effect of the Company’s repurchase and retirement of $128.0 million in aggregate principal amount of the 2030 Notes completed in October 2026, approximately 62.3 million warrants will be issued. This includes around 54.4 million warrants to common stockholders and an additional 7.9 million warrants to the noteholders, in accordance with the terms of those securities.
How much will be raised if all Warrants are exercised?
If all 62.3 million warrants are exercised at the $3.00 per share exercise price, Enovix would receive aggregate exercise consideration of approximately $169.1 million (excluding warrants held by our directors and executive officers), in a combination of cash and 2028 Notes surrendered at face value. The actual amount of proceeds Enovix can receive will depend on the number of warrants ultimately exercised (which will depend on, among other factors, the trading price of our common stock), the payment method selected by holders, and applicable transaction costs.
What do I have to do to receive the Warrants?
You must be an eligible stockholder or noteholder as of the record date to participate in the warrant distribution. The warrants will be issued without any action required by our equity holders and without any payment of cash or other consideration.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 2 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
If you hold shares or convertible notes through a brokerage account, bank, or financial institution and are a holder in street name, contact your broker for further information. If your shares are held in a registered account with Enovix’s transfer agent, contact Client Services at Computershare Trust Company, N.A.
What happens to fractional warrants?
Fractional warrants will not be issued or distributed. If a holder would otherwise be entitled to receive a fractional warrant, the total number of warrants issued to that holder will be rounded down to the nearest whole warrant. As a result, stockholders whose shareholdings are not evenly divisible by four will receive only whole warrants. For example, a stockholder owning 1, 100, or 145 shares of common stock would receive 0, 25, and 36 warrants, respectively.
Is management participating in the distribution?
All stockholders of record, including management stockholders, as of the November 13, 2026 record date are eligible to receive this distribution; however, our directors and executive officers will only realize value on the warrants (on a net exercise basis) if the warrants are in the money on the expiration date; and our directors and executive officers may not otherwise exercise, sell or transfer the warrants.
02 HOW THIS DISTRIBUTION COMPARES WITH 2025
How is this warrant distribution different from Enovix’s 2025 distribution?
This distribution builds on the success of our 2025 program with an added benefit: holders can exercise using cash or 2028 Notes at face value. The warrants can therefore do more than raise capital. They can also retire debt and reduce future interest obligations while keeping cash available for the business.
For stockholders, this combines the same opportunity to participate in Enovix’s future growth with the potential benefit of a stronger balance sheet. Holders retain the choice to exercise, hold or sell their warrants, with an additional way to fund their participation.
What were the results of the 2025 warrant dividend program?
Approximately 26.5 million warrants were exercised, generating approximately $232.1 million in gross proceeds. The program concluded on August 29, 2025, when all remaining warrants were either exercised or expired.
The program demonstrated substantial investor participation and provided additional capital to support Fab2 scale-up and general corporate purposes.
Why is Enovix undertaking another warrant distribution?
Enovix held approximately $512 million in cash, cash equivalents and investments, including restricted cash, as of October 4, 2026. This distribution gives us an opportunity to build on that liquidity by reducing outstanding debt and future interest obligations while keeping cash available to execute our business plans.
Following the strong investor participation in our 2025 program, we are again putting the opportunity to participate directly in existing stockholders’ and noteholders’ hands. The pro rata distribution gives stockholders the opportunity to maintain their proportional ownership on a fully-diluted basis by exercising their warrants if they choose to do so. This distribution also adds the ability to exercise using 2028 Notes at face value, which aligns with the stockholder opportunity to create a stronger balance sheet for the Company.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 3 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
How would this distribution reduce debt, raise cash and support the Company’s business?
Warrants exercised using 2028 Notes would retire the surrendered principal and reduce associated future interest obligations without requiring Enovix to use cash to repay that principal. Enovix would receive no cash proceeds from those exercises.
Warrants exercised for cash would provide additional liquidity for general corporate purposes, including a new source of funding for increasing the Company’s Korean drone battery manufacturing capacity without drawing on existing cash. Together, these payment methods give the Company a path to reduce debt and raise capital while preserving cash for business execution. The amount of debt retired and cash raised will depend on the number of warrants exercised and the payment methods selected by holders.
How much debt could Enovix retire if warrants are exercised using 2028 Notes?
The aggregate exercise price of all warrants being distributed (approximately $169.1 million) is approximately equal to the $172.5 million principal amount of 2028 Notes currently outstanding. If holders exercise a sufficient number of warrants using 2028 Notes, most of the $172.5 million of 2028 Notes could be retired. The actual amount retired will depend on how many warrants are exercised and whether holders choose to pay with cash or 2028 Notes.
03 RECEIVING YOUR WARRANTS
What’s the last day I can buy Enovix shares and still receive the warrants?
To receive the warrant dividend, you must purchase Enovix shares no later than the close of trading on November 12, 2026. Purchases made on or before November 12, 2026 should settle in time for you to be a stockholder of record on November 13, 2026, the official record date, and you should be eligible to receive the warrants.
If you buy shares on November 13, 2026 or later, your purchase will settle after the record date, and you will not receive any warrants. This is because November 13, 2026 is the ex-dividend date—the first trading day on which the shares no longer carry the right to receive the warrant dividend.
I purchased my Enovix shares through an online brokerage account. How will I receive my warrant notice or access the warrants?
Your broker is responsible for crediting your account with the warrants if you held shares as of the record date. You should not need to take action to receive them, but processing times vary. Please contact your broker directly for confirmation and additional information regarding timing and access to the warrants, including the mechanics of warrant sales and exercises.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 4 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
My warrants are not showing up in my brokerage account. What should I do?
Typically, your broker will be responsible for crediting your account with warrants if you held shares as of the record date and such shares are not being pledged as collateral or loaned out. If your shares are being pledged as collateral or loaned out, other mechanics may apply. In all cases you need to contact your broker directly for confirmation and for any other information regarding timing and access to warrants, including the mechanics for warrant sales and exercises.
What happens if I hold my Enovix shares in a margin account and the shares are on loan as of the November 13, 2026 record date?
If your Enovix shares are in a margin account, your broker may loan out your shares – often without notifying you. This is standard practice for margin accounts. If your shares are loaned out at the time of the warrant dividend record date, you are not considered the stockholder of record for purposes of receiving the warrant dividend and will not receive any warrants directly from Enovix.
If your broker has loaned out your shares, instead of receiving actual warrants from Enovix, your broker may instead post a placeholder entry in your account called an “in lieu of” credit. This “in lieu of” warrant credit does not represent an exercisable warrant and you will not be able to exercise or trade your warrant entry unless your broker takes steps to obtain the actual warrants for you, which is not guaranteed.
How do I ensure I receive the actual exercisable Enovix warrants if I have a margin account?
Transfer your shares from a margin account to a cash account (or a fully paid-for account) before the November 13, 2026 record date of the warrant dividend, and confirm with your broker that your shares will be held in your name and not subject to lending or rehypothecation. Processing time varies by broker.
Do non-U.S. stockholders qualify to receive the warrant dividend?
Yes. There are no stated restrictions on international stockholders receiving warrants. If you held Enovix common stock as of the record date through a brokerage account, you should receive the warrants in your account. If you are a non-U.S. stockholder, you should contact your broker for jurisdiction-specific logistics, including with regard to warrant sales and exercises.
I hold listed call options on Enovix common stock. Will I receive the warrant dividend?
No. Only holders of record of our common shares or convertible notes as of the November 13, 2026 record date will receive the warrant dividend. If you hold call options, you must exercise them and own the shares before the record date to receive warrants.
Option holders should also review any notices from the Options Clearing Corporation (“OCC”) to determine if there will be any adjustments to strike prices or deliverables. In connection with the distribution, listed call options may receive an “NS” (non-standard) designation on the record date. NS-designated options are not exercisable through automated systems and generally require manual exercise through your brokerage firm. Option holders should contact their brokerage firm for details regarding exercise procedures and timing.
How are the warrants handled for shares held in a retirement account?
Warrants will be credited to your retirement brokerage account if you held shares as of the record date. However, exercising or selling warrants from within a retirement account may be subject to additional rules or restrictions. Please consult your retirement account custodian or tax advisor.
What if I hold a short position?
If you are short Enovix stock as of the record date, you will be required on the distribution date to deliver the pro rata number of warrants to the lender of the shares you borrowed. As a result, market participants with short positions may need to purchase warrants in the open market to meet this delivery obligation.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 5 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
04 EXERCISE PRICE, EXPIRATION AND EARLY EXPIRATION
What is the Exercise Price?
Each warrant entitles the holder to purchase one share of Enovix common stock at an exercise price of $3.00. The exercise price may be paid in cash or by surrendering 2028 Notes at face value, as described in Section 05.
What is the Expiration Date?
The warrants will expire on April 28, 2028, unless the Early Expiration Price Condition is met.
What is the Early Expiration Price Condition?
If, during any 30 consecutive trading days, the volume-weighted average price (VWAP) of Enovix common stock is at or above $3.30 for at least 20 of those days (not necessarily consecutive), then the warrants will expire early — specifically at 5:00 p.m. New York City time on the business day immediately following that 30-day period or such other date as the Company may elect in accordance with the warrant agreement.
Enovix will issue a press release if the Early Expiration Price Condition is triggered.
When does the 20 out of 30-day VWAP measurement period for the Early Expiration Price Condition begin?
The 20 out of 30-day VWAP measurement period can begin on the first trading day after the distribution date. If Enovix shares are trading at or above $3.30 on that day and the VWAP meets the threshold, that day counts as the first of the 20 qualifying days within the 30-trading-day window.
If the VWAP Early Expiration Price Condition is met, for example, on the 20th qualifying day, when do the warrants expire?
The warrants will expire on the business day immediately following the 20th qualifying trading day within any 30-day period, unless the Company announces an alternate expiration date in accordance with the warrant agreement.
How will I know if the warrants are about to expire?
If the warrants are scheduled to expire, either on the final expiration date or due to early expiration, Enovix will issue a public press release announcing the expiration date. This notice will be made available as promptly as practicable and will include the exact date and time by which warrant exercises must be completed.
We encourage stockholders to monitor Enovix’s Investor Relations website (https://ir.enovix.com) for news announcements and updates, as well as our filings with the SEC at www.sec.gov.
Can my broker impose an earlier deadline to exercise than Enovix’s expiration time?
Yes. Your broker may require an earlier instruction deadline than the stated expiration time of the warrants and may require you to submit notices by specific methods. We recommend confirming your broker’s procedures, cut-offs and method of notice well in advance. Enovix also intends to issue a public press release reminder ahead of expiration.
What happens if the share price does not go up?
Holders may exercise their warrants at any time before expiration. If the stock price does not reach or exceed the early expiration price of $3.30 for 20 out of 30 consecutive trading days, the warrants will remain outstanding until their final expiration on April 28, 2028. If the stock never triggers early expiration, holders retain full control over their participation through the end of the term.
What happens if I do not exercise the warrants before they expire?
If you do not sell or exercise your warrants by the applicable expiration date, which may occur early as described above, such warrants will expire and have no value. Your rights under the warrants will lapse with no further action required or penalty.
You can choose to hold the warrants until expiration, sell them, or exercise them before expiration. If you take no action, the warrants simply expire. If other warrant holders exercise and new shares of common stock are issued to them while you do not exercise your warrants, your percentage ownership in Enovix’s common stock will decline.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 6 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
05 EXERCISING YOUR WARRANTS
When can I exercise my warrants?
You may exercise the warrants with cash at any time from the distribution date until 5:00 p.m. New York City time on the April 28, 2028 expiration date, or one business day after the date on which the Early Expiration Price Condition is reached (unless Enovix specifies an alternate expiration date as described in the warrant agreement).
You may also exercise the warrants with 2028 Notes at any time from the distribution date until the Early Exercise Expiration Price Condition is reached, as described in the warrant agreement.
How do I exercise my warrants?
If you hold the warrants through a brokerage account, bank or financial institution and are thus a holder in street name, you should contact your broker, bank or other financial institution intermediary for information on how to exercise warrants. You may also contact Computershare Trust Company, N.A., the warrant agent, at 150 Royall Street, Canton, MA 02021, Attention: Client Services, telephone 1-877-373-6374, if you have additional questions about the exercise process. You can pay with cash or 2028 Notes using the following methods.
To exercise for cash, you may instruct your broker to submit your exercise through the Depository Trust Company’s (“DTC”) WARR service and arrange payment of the cash exercise price.
To exercise using 2028 Notes, you may instruct your broker to submit your warrants and notes through DTC’s electronic system, known as ATOP. Computershare will review the submissions, and accepted exercises will settle on a weekly schedule. Accrued interest on accepted notes, calculated through the applicable allocation date, will be paid in cash along with your shares, based on the schedule in Exhibit C to the warrant agreement. Submission deadlines and settlement dates will be specified in the applicable DTC event announcements.
You can also exercise directly with Computershare, the warrant agent, using cash or 2028 Notes. For this method, you must submit a completed election to purchase warrant shares, included in Exhibit A to the warrant agreement, and arrange the applicable payment and delivery of securities. Your broker can arrange the required securities deliveries through DTC’s DWAC system, which allows securities to be transferred to and from the warrant agent. No separate accrued-interest payment is made for notes surrendered through this method.
If you are a direct registration holder, to exercise your warrants, you must provide payment to Computershare Trust Company, N.A. either (i) in United States dollars by certified or official bank check or wire transfer of immediately available funds to an account designated by Enovix or (ii) by the surrender of 2028 Notes having a face value, in each case, equal to $1,000 for every 333 warrants exercised. Such payment must specify the name of the holder and the number of warrants exercised. You also are required to present the election to purchase warrant shares attached to the warrant.
If you have any questions or cannot locate your warrant statement, please contact Computershare Trust Company, N.A., as warrant agent.
Please refer to the warrant agreement, including the section relating to “exercise terms” and the form of election to purchase warrant shares exhibit to the warrant agreement, which will be filed with the SEC together with the Form 8-A to register the warrants, at or prior to the distribution date.
How do I pay the exercise price, and how will the warrants be settled upon exercise?
The exercise price of the warrants is $3.00. A warrant holder may exercise their warrants at any time for cash, and exercises may be made with 2028 Notes, as will be specified under the terms in the warrant agreement. A warrant holder who surrenders 2028 Notes will be credited the $1,000 face value of those notes against the exercise price of the warrants, regardless of the notes’ trading price.
For purposes of payment of the exercise price, $1,000 principal amount of 2028 Notes shall be deemed to be equal to the aggregate exercise price for 333 warrants. Note exercises will be calculated using this fixed ratio, rather than by dividing the principal amount delivered by the cash exercise price, subject to adjustments provided in the warrant agreement. Only after the payment of the exercise price will holders receive shares of the Company’s common stock.
For example, a holder who exercises 333,000 warrants and delivers $1,000,000 face value of 2028 Notes will receive 333,000 shares. Holders of 2028 Notes who are not also stockholders of record may purchase additional warrants in the market in order to deliver a larger amount of their 2028 Notes to exercise warrants for shares of common stock.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 7 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Can I purchase warrants or 2028 Notes in the open market to participate?
Yes. Holders of Enovix’s 2028 Notes may purchase additional warrants in the open market and exercise them using their notes. Stockholders who receive warrants in the distribution may also purchase 2028 Notes in the open market to pay the exercise price instead of cash. Other investors may purchase both warrants and 2028 Notes in the open market and submit them for exercise to receive Enovix common shares, in accordance with the warrant terms and exercise procedures.
Which Enovix notes are eligible for exercise?
Effective on the distribution date, notes of the following series issued by Enovix may be used to pay the exercise price:
| TITLE OF SERIES | CUSIP / ISIN | PRINCIPAL AMOUNT OUTSTANDING | CONSIDERATION PER $1,000 PRINCIPAL AMOUNT SURRENDERED | |||||
| 3.00% Convertible Senior Notes due 2028 | 293594AC1 / US293594AC17 | $ | 172,500,000 | Warrant exercise price valued at the aggregate principal amount of the notes surrendered (regardless of the then-current market value of such notes), excluding any accrued and unpaid interest. | ||||
Enovix may add or remove the right to use a particular series of notes to pay the exercise price, provided that Enovix will give at least 20 business days’ notice before removing a series of notes from being eligible to pay the warrant exercise price. If we decide to add or remove notes, we will promptly make a public announcement, update our website and the corresponding table to reflect the change.
What happens if I surrender more in principal amount of notes than I exercise in warrants?
The principal amount of any 2028 Notes surrendered to exercise warrants in excess of the exercise price shall be forfeited to Enovix and will not be refunded unless the excess is greater than $1,000, in which case Enovix will return any notes in multiples of $1,000 principal amount pursuant to the terms of the warrant agreement.
If I use notes to pay for the exercise of the warrants, will I receive accrued interest?
If your broker submits your warrants and 2028 Notes through DTC’s ATOP system, accrued interest on the accepted notes, calculated through the applicable allocation date, will be paid in cash along with your shares on the weekly settlement date. The amount will be determined using the accrued-interest schedule in Exhibit C to the warrant agreement.
If you instead exercise directly with Computershare using the DWAC process, you will not receive a separate accrued-interest payment.
For notes surrendered after the coupon record date and before the corresponding coupon payment date, no separate accrued-interest payment will be made for the exercise. Instead, the normal coupon will be paid to the holder entitled to it as of the record date, in accordance with the applicable indenture.
Please confirm with your broker which exercise method to use.
06 TRADING THE WARRANTS
Will the Warrants trade publicly?
Yes. The warrants are expected to be listed on Nasdaq under the ticker symbol ENVXW and to begin trading on or about November 19, 2026, the first trading day after the distribution date.
Can I sell my Warrants?
Yes. The warrants are expected to be tradeable on Nasdaq. You can choose to hold, exercise, or sell them based on your financial objectives. Your ability to sell the warrants will depend, in part, on whether a trading market develops for the warrants.
07 WHY THIS STRUCTURE
Will this dilute my ownership?
There is no immediate dilution when we issue the warrants. New shares will only be issued if warrants are exercised and the Company receives the exercise price, in cash or in 2028 Notes. Unlike a traditional equity raise, this structure allows you to maintain your proportional ownership and avoid dilution by exercising your warrants.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 8 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
What will the Company use the proceeds for?
Enovix intends to use any cash proceeds from the exercise of the warrants for general corporate purposes, including reducing existing debt. Exercise of warrants in exchange for 2028 Notes will not result in any cash proceeds to Enovix but will reduce the amount of debt Enovix has outstanding and associated interest expense. In either event, we expect this to be a deleveraging transaction.
Why is the Company using this structure instead of a traditional equity raise?
The warrant dividend puts the opportunity to participate in the Company’s equity issuance directly in the hands of existing stockholders and noteholders. Recipients receive warrants in proportion to their existing holdings and can choose to exercise them, hold them or sell them to realize any available market value, without an obligation to invest additional funds.
The warrants serve two purposes: cash exercises would raise additional capital, while exercises using 2028 Notes at face value would retire outstanding debt and reduce associated future interest obligations without requiring Enovix to use cash to repay that principal. This gives the Company a path to both cash generation and debt reduction while preserving cash for the business and giving existing investors the opportunity to participate in its future growth.
Why would stockholders want this structure?
It gives our stockholders free optionality to choose what they want to do. Those who believe in our strategy gain the right, without any obligation, to buy more stock at a fixed, attractive price in the future. If we execute well, they benefit. If not, they’ve risked nothing. Holders also have the flexibility to sell their warrants and realize immediate value. We’re putting choice and timing in our stockholders’ hands.
Stockholders will also benefit from Enovix’s reduced leverage following the exercise of warrants with outstanding notes and from the Company’s increased cash position from warrants exercised with cash.
Our goal is to scale responsibly while protecting stockholder interests. This structure ensures capital is available when operational success justifies it, reinforcing long-term discipline and financial readiness, without pressuring the Company to raise funds under suboptimal conditions.
Why would noteholders want this structure?
Noteholders benefit as their 2028 Notes may be used to exercise warrants at the face value of the notes, regardless of the notes’ trading price. Upon exercise with the 2028 Notes, the leverage ratios of the Company will improve.
08 TAX CONSIDERATIONS
What are the tax implications?
The U.S. federal income tax consequences of the warrant dividend are complex and may vary based on each stockholder’s individual circumstances. Stockholders are encouraged to consult with their tax advisor to understand how the distribution may affect their individual tax situation.
For U.S. taxpayers, how will the warrant exercise be treated for tax purposes?
For U.S. taxpayers who receive warrants, this will generally not be a taxable event. However, if you exercise the warrants and later sell the resulting shares, you may incur capital gains taxes. In the event you exercise your warrants in exchange for shares, your cost basis for those shares will be the $3.00 exercise price, plus any transaction costs incurred.
The U.S. federal income tax treatment of the warrant distribution may vary based on an investor’s specific circumstances. Enovix does not provide tax advice. Investors are encouraged to consult their tax advisor regarding the potential impact of the distribution.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 9 |
![]() |
WARRANT DIVIDEND FAQ ● NOVEMBER 2026 |
Additional details will be provided in the tax reporting section of the prospectus supplement, which Enovix expects to file with the SEC on the distribution date.
09 OTHER QUESTIONS
Are there risks to me of the warrants?
Yes. Like any security, the warrants involve risks. For example, they could expire with no value if not exercised, trading/liquidity may be limited, and early expiration can shorten the time to act. Please review the “Risk Factors” in Enovix’s prospectus supplement that we intend to file in connection with the warrants and our other filings with the SEC for a more detailed discussion.
Can Enovix change the terms of the warrants?
The procedures relating to any amendments or adjustments to the terms of the warrants will be set forth in the warrant agreement.
Can I receive a copy of the full warrant agreement?
Yes. Enovix expects to file the full warrant agreement with the SEC on or prior to the distribution date. It will be available via the SEC’s EDGAR system at www.sec.gov and on the Enovix Investor Relations page at ir.enovix.com.
Where can I find more information?
More information will be available in our investor presentation and our filings with the SEC. You may also contact Enovix Investor Relations at ir@enovix.com.
IMPORTANT INFORMATION
This document is provided for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities. The warrants and the shares of common stock issuable upon exercise will be offered pursuant to a registration statement on Form S-3 and a prospectus supplement filed with the SEC. Investors should read the prospectus supplement, the warrant agreement and Enovix’s other filings with the SEC, which contain important information, including risk factors, before making any investment decision. Statements regarding expected dates, amounts and outcomes are forward-looking and subject to change. Enovix does not provide tax, legal or investment advice; please consult your own advisors.
FORWARD-LOOKING STATEMENTS
This FAQ contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected record date, distribution date, listing and expiration of the warrants; the number of warrants to be issued; the number of warrants that may be exercised and the payment methods holders may select; the amount of cash raised or 2028 Notes retired; the expected benefits of the warrant dividend, including reduced debt and interest expense; the anticipated use of proceeds; and the expected tax treatment of the distribution. These statements are based on management’s current expectations and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties, including the possibility that few or no warrants are exercised, that the distribution is delayed or modified, or that the cash proceeds received or debt retired differ materially from our expectations; volatility in the trading price of our common stock and warrants; and the other risks described in the “Risk Factors” sections of our annual report on Form 10-K, our quarterly reports on Form 10-Q and the prospectus supplement relating to the warrants, each filed or to be filed with the SEC and available at https://ir.enovix.com and www.sec.gov. Forward-looking statements speak only as of the date of this document, and Enovix undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise.
ENOVIX CORPORATION ● NASDAQ: ENVX ● IR@ENOVIX.COM | 10 |
